Sirna duplex and conjugate for targeted regulation of inhbe gene expression and use thereof

HK40137273APending Publication Date: 2026-09-11BEIJING YUEKANGKECHUANG PHARM TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK42026125466
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-13
Filing Date
2026-06-29
Publication Date
2026-09-11
Patent Text Reader

Abstract

The invention discloses a siRNA duplex for targeted regulation and control of INHBE gene expression and application of the siRNA duplex in prevention and treatment of metabolism-related diseases. The present disclosure also relates to corresponding conjugates and pharmaceutical compositions. Cell and animal experiment results show that the oligonucleotide duplex can obviously inhibit the expression of the INHBE gene, and can be used for preparing medicines for preventing or treating related diseases such as atherosclerosis.
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202610282198.X (22) Application Date 2026.03.10 (66) Domestic Priority Data 202510608772.1 2025.05.12 CN 202510614795.3 2025.05.13 CN (71) Applicant Beijing Yuekang Kechuang Pharmaceutical Technology Co., Ltd. Address Room 101, 1st Floor, Building 3, No. 11, Kechuang 7th Street, Daxing District, Beijing 100176, China (72) Inventors Huang Ze'ao, Song Gengshen, Ji Guangshan, Yang Shuo, Yu Fei, Fu Rui, Wu Yucheng (74) Patent Agency Shanghai Bixing Law Firm 31283 Patent Attorney Huang Yishu (51) Int.Cl. C12N 15 / 113(2010.01) C12N 9 / 22(2006.01) A61K 31 / 713(2006.01) A61K 47 / 54(2017.01) A61K 38 / 46(2006.01) A61P 3 / 10(2006.01) A61P 3 / 04(2006.01) A61P 3 / 06(2006.01) A61P 5 / 50(2006.01) A61P 1 / 16(2006.01) A61P 9 / 12(2006.01) A61P 3 / 00(2006.01) A61P 9 / 10(2006.01) (54) Invention Title: siRNA Double Struts Targeting INHBE Gene Expression, Conjugates, and Their Applications (57) Abstract: This invention discloses siRNA double strands targeting INHBE gene expression and their use in the prevention and treatment of metabolic-related diseases. This disclosure also relates to corresponding conjugates and pharmaceutical compositions. Cell and animal experimental results show that the oligonucleotide double strands of this disclosure can significantly inhibit INHBE gene expression and can be used to prepare drugs for the prevention or treatment of atherosclerosis and other related diseases. Claims (22 pages), Description (91 pages), Sequence Listing (Electronic Publication) CN 121801914 A 2026.04.07 CN 1 21 80 19 14 A 1. A double-stranded siRNA, characterized in that the double-stranded siRNA comprises a sense strand and an antisense strand forming an inverse complementary double-stranded region, the antisense strand comprising at least 15, 16, 17, 18, or 19 consecutive nucleotides complementary to a target sequence as shown in SEQ ID NO: 907, or the antisense strand comprising, as shown in SEQ ID NO: 13~24, 134~1. At least 15, 16, 17, 18, or 19 consecutive nucleotide fragments in any of the sequences shown in SEQ ID NO: 1-12, 25-127, 129-131, or 243-251. 2. The siRNA duplex as claimed in claim 1, wherein the sense strand comprises at least 17, 18, or 19 consecutive nucleotide fragments in any of the sequences shown in SEQ ID NO: 1-12, 25-127, 129-131, or 243-251. 3. The siRNA duplex as claimed in claim 1, wherein the siRNA duplex satisfies one or more of the following conditions: (1) the length of the reverse complementary double-stranded region is 17-21 bp; (2) the lengths of the sense strand and the antisense strand are each independently comprised of 19-23 nucleotides; (3) at least one strand contains a 3' overhang of at least one or at least two nucleotides; and, (4) the siRNA duplex is an siRNA for inhibiting the expression of the INHBE gene. 4. The siRNA duplex as claimed in claim 1, characterized in that the siRNA duplex comprises any one or a combination of at least two of the following oligonucleotide duplexes composed of paired sense and antisense strands: the nucleotide sequence of the sense strand is shown in SEQ ID NO: 1; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 13; the nucleotide sequence of the sense strand is shown in SEQ ID NO: 2; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 14; the nucleotide sequence of the sense strand is shown in SEQ ID NO: 3; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 15; the nucleotide sequence of the sense strand is shown in SEQ ID NO: 4; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 16; the nucleotide sequence of the sense strand is shown in SEQ ID NO: 5; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 17; the nucleotide sequence of the sense strand is shown in SEQ ID NO: 6; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 18; The nucleotide sequence of the positive strand is shown in SEQ ID NO: 7; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 19; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 8; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 20; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 9; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 21; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 10; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 22;The nucleotide sequence of the positive strand is shown in SEQ ID NO: 11; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 23; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 12; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 24; The nucleotide sequence of the positive strand is shown in SEQ ID NO: 25; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 134; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 26; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 135; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 27; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 136; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 28; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 137; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 137. The nucleotide sequence of the positive strand is shown in SEQ ID NO: 29; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 138; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 30; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 139; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 31; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 140; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 32; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 141; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 33; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 142; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 34; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 143; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 35; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 144; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 144. The nucleotide sequence of the positive strand is shown in SEQ ID NO: 36; the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 145; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 37; the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 146; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 38; the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 147; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 147.The nucleotide sequence of the positive strand is shown in SEQ ID NO: 149; the nucleotide sequence of the negative strand is shown in SEQ ID NO: 148; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 40; the nucleotide sequence of the negative strand is shown in SEQ ID NO: 149; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 41; the nucleotide sequence of the negative strand is shown in SEQ ID NO: 150; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 42; the nucleotide sequence of the negative strand is shown in SEQ ID NO: 151; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 43; the nucleotide sequence of the negative strand is shown in SEQ ID NO: 152; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 44; the nucleotide sequence of the negative strand is shown in SEQ ID NO: 153; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 45; the nucleotide sequence of the negative strand is shown in SEQ ID NO: 153; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 45; the nucleotide sequence of the negative strand is shown in SEQ ID NO: 153; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 45; the nucleotide sequence of the negative strand is shown in SEQ ID NO: 153; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 44; the nucleotide sequence of the negative strand is shown in SEQ ID NO: 153; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 45 ...1 The nucleotide sequence of the positive strand is shown in SEQ ID NO: 154; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 46; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 155; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 47; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 156; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 48; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 157; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 49; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 158; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 50; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 159; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 51; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 160; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 52; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 160; The nucleotide sequence of the positive strand is shown in SEQ ID NO: 161; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 53; and the nucleotide sequence of the negative strand is shown in SEQ ID NO: 162; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 54; and the nucleotide sequence of the negative strand is shown in SEQ ID NO: 163; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 55; and the nucleotide sequence of the negative strand is shown in SEQ ID NO: 163.The nucleotide sequence of the positive strand is shown in SEQ ID NO: 164; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 56; and the nucleotide sequence of the negative strand is shown in SEQ ID NO: 165; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 57; and the nucleotide sequence of the negative strand is shown in SEQ ID NO: 166; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 58; and the nucleotide sequence of the negative strand is shown in SEQ ID NO: 167; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 59; and the nucleotide sequence of the negative strand is shown in SEQ ID NO: 168; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 60; and the nucleotide sequence of the negative strand is shown in SEQ ID NO: 169; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 61; and the nucleotide sequence of the negative strand is shown in SEQ ID NO: 170; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 62; and the nucleotide sequence of the negative strand is shown in SEQ ID NO: 166. As shown in NO: 171; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 63; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 172; Claims 3 / 22 Page 4 CN 121801914 A The nucleotide sequence of the positive strand is shown in SEQ ID NO: 64; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 173; The nucleotide sequence of the positive strand is shown in SEQ ID NO: 65; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 174; The nucleotide sequence of the positive strand is shown in SEQ ID NO: 66; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 175; The nucleotide sequence of the positive strand is shown in SEQ ID NO: 67; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 176; The nucleotide sequence of the positive strand is shown in SEQ ID NO: 68; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 177; The nucleotide sequence of the positive strand is shown in SEQ ID NO: 69; and the nucleotide sequence of the negative strand is shown in SEQ ID NO: 178; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 70; and the nucleotide sequence of the negative strand is shown in SEQ ID NO: 179; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 71; and the nucleotide sequence of the negative strand is shown in SEQ ID NO: 180;The nucleotide sequence of the positive strand is shown in SEQ ID NO: 72; and the nucleotide sequence of the negative strand is shown in SEQ ID NO: 181; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 73; and the nucleotide sequence of the negative strand is shown in SEQ ID NO: 182; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 74; and the nucleotide sequence of the negative strand is shown in SEQ ID NO: 183; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 75; and the nucleotide sequence of the negative strand is shown in SEQ ID NO: 184; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 76; and the nucleotide sequence of the negative strand is shown in SEQ ID NO: 185; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 77; and the nucleotide sequence of the negative strand is shown in SEQ ID NO: 186; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 78; and the nucleotide sequence of the negative strand is shown in SEQ ID NO: 187; The nucleotide sequence of the positive strand is shown in SEQ ID NO: 79; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 188; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 80; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 189; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 81; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 190; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 82; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 191; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 83; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 192; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 84; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 193; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 193; The nucleotide sequence of the positive strand is shown in SEQ ID NO: 85; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 194; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 86; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 195; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 87; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 196; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 196.The nucleotide sequence of the positive strand is shown in SEQ ID NO: 88; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 197; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 89; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 198; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 90; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 199; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 91; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 200; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 92; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 201; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 93; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 202; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 94; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 203 ...95; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 95; the nucleotide sequence of the positive strand The nucleotide sequence of the positive strand is shown in SEQ ID NO: 95; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 204; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 96; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 205; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 97; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 206; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 98; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 207; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 99; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 208; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 100; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 209; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 101; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 210; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 101; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 210; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 209; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 201; and the nucleotide sequence of the antisense ... The nucleotide sequence of the positive strand is shown in SEQ ID NO: 102; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 211; Claims 5 / 22 page 6 CN 121801914 A The nucleotide sequence of the positive strand is shown in SEQ ID NO: 103; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 212; The nucleotide sequence of the positive strand is shown in SEQ ID NO:The nucleotide sequences of the positive strand and the antisense strand are shown in SEQ ID NO: 104; SEQ ID NO: 105; SEQ ID NO: 214; SEQ ID NO: 106; SEQ ID NO: 215; SEQ ID NO: 107; SEQ ID NO: 216; SEQ ID NO: 108; SEQ ID NO: 217; SEQ ID NO: 109; SEQ ID NO: 218; SEQ ID NO: 110; SEQ ID NO: 219. The nucleotide sequence of the positive strand is shown in SEQ ID NO: 111; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 220; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 112; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 221; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 113; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 222; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 114; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 223; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 115; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 224; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 116; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 225; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 117; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 118. As shown in SEQ ID NO: 226; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 118; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 227; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 119; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 228; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 120; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 229;The nucleotide sequence of the positive strand is shown in SEQ ID NO: 121; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 230; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 122; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 231; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 123; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 232; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 124; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 233; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 125; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 234; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 126; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 235 ...3; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 234; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 125; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 234; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 126; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 235; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 123; the The nucleotide sequence of the positive strand is shown in SEQ ID NO: 127; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 236; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 129; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 238; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 130; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 239; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 131; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 240; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 243; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 252; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 244; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 253; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 245; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 254; The nucleotide sequence of the positive strand is shown in SEQ ID NO: 246; and the nucleotide sequence of the negative strand is shown in SEQ ID NO: 255; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 247; and the nucleotide sequence of the negative strand is shown in SEQ ID NO: 256; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 248; and the nucleotide sequence of the negative strand is shown in SEQ ID NO: 257;The nucleotide sequence of the positive strand is shown in SEQ ID NO: 249; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 258; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 250; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 259; the nucleotide sequence of the positive strand is shown in SEQ ID NO: 251; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 260. 5. The siRNA duplex as claimed in claim 1, characterized in that the sense strand or antisense strand comprises at least one modified nucleotide, said at least one modified nucleotide being selected from any one or a combination of at least two of the following: deoxy-nucleotides, 3'-terminal deoxy-thymidine (dT) nucleotides, 2'-O-methyl modified nucleotides, 2'-fluorine modified nucleotides, 2'-deoxy-modified nucleotides, locked nucleotides, non-locked nucleotides, configuration-restricted nucleosides, restricted ethyl nucleotides, baseless nucleotides, 2'-amino-modified nucleotides, 2'-O-allyl-modified nucleotides, 2'-C-alkyl-modified nucleotides, 2'-hydroxy-modified nucleotides, 2'-methoxyethyl-modified nucleotides, 2'- O-alkyl-modified nucleotides, morpholinonucleotides, aminophosphates, nucleotides containing non-natural bases, tetrahydropyran-modified nucleotides, 1,5-dehydrohexyl-modified nucleotides, cyclohexenyl-modified nucleotides, nucleotides containing thiophosphate groups, nucleotides containing methylphosphate groups, nucleotides containing 5'-phosphates, and nucleotides containing 5'-phosphate mimics. 6. The siRNA duplex of claim 5, wherein the nucleotide modification on the sense and antisense strands is a 2'-position modification of the nucleotide ribose. 7. The siRNA duplex of claim 6, wherein the 2'-position modification of the nucleotide ribose is selected from any one or a combination of several of 2'-methoxy, 2'-methoxyethyl, 2'-fluoro, 2'-benzyloxy, 2'-methylcarbonylamino, and 2'-pyridinemethoxy. 8. The siRNA duplex of claim 7, wherein the 2'-position modification of the nucleotide ribose is an alternating combination of 2'-methoxy and 2'-fluoro. 9. The siRNA duplex as described in claim 8, characterized in that the 2' position of the nucleotide ribose is modified as follows: odd-numbered positions on the sense strand are all 2'-fluorinated, and even-numbered positions are all 2'-methoxyinated; and odd-numbered positions on the antisense strand are all 2'-methoxyinated, and even-numbered positions are all 2'-fluorinated. 10. The siRNA duplex as described in claim 1, characterized in that the nucleotide monomers are connected by a 3',5'-phosphodiester.The siRNA duplex is connected to each other by a 3',5'-phosphothioester bond or a 3',5'-phosphothioester bond. 11. The siRNA duplex as claimed in claim 1, characterized in that the 3',5'-phosphothioester bonds between nucleotides at the end of the siRNA duplex sequence contain a thiomodification and form chiral pure 3',5'-phosphothioester bonds; preferably, the first to fourth nucleotides at the 5' end of the sense strand and / or the antisense strand contain one, two, or three 3',5'-phosphothioester bonds, and the first to fourth nucleotides at the 3' end of the antisense strand contain one, two, or three 3',5'-phosphothioester bonds. 12. The siRNA duplex as described in claim 1, characterized in that the 5' carbon atom of the modified antisense strand 5' terminal nucleotide glycoside is phosphorylated, wherein the phosphorylation of the 5' carbon atom is selected from the following 5' phosphorylation groups: 5'-vinylphosphonate group (5'-E-VP); 5'-methylphosphonate group (5'-MP); 5'-C-methylphosphate group; 5'-thiophosphate group (5'-PS) and 5'-phosphate group (5'-P), the structures of which are shown below: ; wherein R is hydrogen, hydroxyl, amino, C1-4 alkyl, aromatic, C1-4 alkoxy, C1-4 alkyl carbonyl amino or halogen; the base is selected from adenine, guanine, cytosine, thymine and uracil. 13. The siRNA duplex as claimed in claim 1, characterized in that the siRNA duplex has the following modifications: The antisense strand has any one of the following modifications: Claim 8 / 22 page 9 CN 121801914 A Claim 9 / 22 page 10 CN 121801914 A and / or, the sense strand has one of the following modifications: Wherein, 2'-OMe represents 2'-methoxy; 2'-F represents 2'-fluoro; PS represents a nucleotide starting from the 5' end, where the nucleotide at this position is connected to its right-side adjacent nucleotide by a 3',5'-thiophosphate bond; EVP represents 5'-vinyl-(E)-phosphonate; Or, the antisense strand has any one of the following modifications: Claim 10 / 22 page 11 CN 121801914 A Claim 11 / 22 page 12 CN 121801914 A and / or, the sense strand has one of the following modifications: Wherein, 2'-OMe represents 2'-methoxy; 2'-F represents 2'-fluoro; PS indicates that the nucleotide at the 5' end is connected to its adjacent nucleotide on the right by a 3',5'-thiophosphate bond; EVP represents 5'-vinyl-(E)-phosphonate. 14. The siRNA duplex as described in claim 13, characterized in that:The antisense chain is modified by modification method B, and the justice chain is modified by modification method a; The antisense chain is modified by modification method C, and the justice chain is modified by modification method a; The antisense chain is modified by modification method C, and the justice chain is modified by modification method b; The antisense chain is modified by modification method D, and the justice chain is modified by modification method b; The antisense chain is modified by modification method E, and the justice chain is modified by modification method b; The antisense chain is modified by modification method F, and the justice chain is modified by modification method b; The antisense chain is modified by modification method G, and the justice chain is modified by modification method b; or The antisense chain is modified by modification method H, and the justice chain is modified by modification method b; Or, The antisense chain is modified by modification method B', and the justice chain is modified by modification method a'; The antisense chain is modified by modification method C', and the justice chain is modified by modification method a'; The antisense chain is modified by modification method C', and the justice chain is modified by modification method b'; The antisense chain is modified by modification method D', and the justice chain is modified by modification method b'. The antisense strand is modified by modification method E', and the sense strand is modified by modification method b'; the antisense strand is modified by modification method F', and the sense strand is modified by modification method b'; the antisense strand is modified by modification method G', and the sense strand is modified by modification method b'; or the antisense strand is modified by modification method H', and the sense strand is modified by modification method b'. 15. The siRNA duplex according to any one of claims 1-14, characterized in that the siRNA duplex comprises any one or a combination of at least two of the oligonucleotide duplexes formed by the pairing of sense and antisense strands shown in Tables 5 and 12. 16. The siRNA duplex as claimed in claim 1, characterized in that, from the 5' end of the antisense strand and / or the sense strand, at any position or at least two positions from the second to the eleventh position are modified with a modifying group, wherein the modifying group is selected from UNA, GNA, and DNA, wherein the structures of UNA and GNA are as follows: ; wherein, the bases are selected from adenine, guanine, cytosine, thymine, and uracil; preferably, the 7th position, or the 7th and 11th positions of the antisense strand are replaced with DNA, and the nucleotides at the complementary pairing position to the 7th position of the antisense strand in the sense strand are also replaced with DNA. 17. An siRNA conjugate, characterized in that, the conjugate comprises the siRNA duplex as claimed in any one of claims 1-16, and a conjugation group connected thereto. 18. The conjugate as claimed in claim 17, characterized in that, the conjugation group is connected to the oligonucleotide sense strand.3'-terminus or 5'-terminus; and / or, the conjugating group is a GalNAc derivative attached using a divalent or trivalent branched linker arm. 19. The conjugation of claim 17, wherein the conjugating group is: , wherein X is a hydroxyl protecting group or H, the hydroxyl protecting group being selected from acetyl, benzoyl, or isobutyryl; Y is an amine protecting group or H, the amine protecting group being selected from formyl, acetyl, propionyl, n-butyryl, or isobutyryl; n is an integer from 0 to 20; q, r, and s are independently integers from 1 to 7. 20. The conjugation of claim 19, wherein the conjugating group is: Claims 13 / 22 pages 14 CN 121801914 A. 21. The conjugate according to claim 17, characterized in that the conjugating group is: wherein X is oxygen, -N(Y)- or sulfur; Y is C1-4 alkyl or C6-10 aryl; R1 is oxygen or sulfur; R2 is hydrogen, -NH2, C1-4 alkyl, C6-10 aryl, C1-4 alkoxy or halogen; A is -(CH2)a-, -(CH2CH2O)b-, -((CH2)cNHCO)d- or -((CH2)cCONH)d-, wherein a is an integer from 1 to 15, b is an integer from 1 to 7, c is an integer from 1 to 7, and d is an integer from 1 to 5; B is -(CH2)e-, wherein e is an integer from 0 to 7; L is -CONH- or -NHCO-; X1 is -(CH2)f- or -(CH2CH2O)fCH2-, f is an integer from 1 to 5; X2 is -(CH2)g-, where g is an integer from 1 to 6; Y1 is 0 or 1; Y2 is 0, 1, or 2; when Y3 is 1, X3 is CH2; when Y3 is 2, X3 is CH; when Y3 is 3, X3 is carbon; m is an integer from 0 to 4; n is an integer from 0 to 4. 22. The conjugate according to claim 21, characterized in that the conjugate group is G4, G5, G6, or G7, with the following structure: , Claims 14 / 22, page 15, CN 121801914 A, , . 23. The conjugate according to claim 17, characterized in that the conjugate has any of the following structures: , , Claims 15 / 22, page 16, CN 121801914 A, , and. 24. The conjugate according to claim 17, wherein the conjugate group is: , wherein X is oxygen, -N(Y)- or sulfur; Y is C1-4 alkyl or C6-10 aryl; R1 is oxygen or sulfur; R2 is hydrogen, -NH2, C1-4 alkyl, C6-10 aryl, C1-4 alkoxy or halogen;A is -(CH2)a-, -(CH2CH2O)b-, -((CH2)cNHCO)d-, or -((CH2)cCONH)d-, where a is an integer from 1 to 15, b is an integer from 1 to 7, c is an integer from 1 to 7, and d is an integer from 1 to 5; B is -(CH2)e-, where e is an integer from 0 to 7; L is -CONH- or -NHCO-; X1 is -(CH2)f- or -(CH2CH2O)fCH2-, where f is an integer from 1 to 5; X2 is -(CH2)g-, where g is an integer from 1 to 6; X3 is oxygen or sulfur; Y1 is 0 or 1; Claims 16 / 22, page 17, CN 121801914 A Y2 is 0, 1, or 2; When Y3 is 1, X4 is CH2; when Y3 is 2, X4 is CH; when Y3 is 3, X3 is carbon; m is an integer from 0 to 4; n is an integer from 0 to 4; q is an integer from 0 to 4. 25. The conjugate according to claim 24, wherein the conjugate group is G101, G102, G103, G105, or G106: (Claims 17 / 22, page 18, CN 121801914 A), or (Claims 18 / 22, page 19, CN 121801914 A). 26. The conjugate according to claim 25, wherein the conjugate has any of the following structures: (Claims 19 / 22, page 20, CN 121801914 A), (Claims 20 / 22, page 21, CN 121801914 A), or... 27. The conjugate of claim 17, wherein the siRNA duplex comprises any one or a combination of at least two of the oligonucleotide duplexes formed by pairing sense and antisense strands as shown in Tables 5, 12 and 16; wherein any one or both of the sense and antisense strands are linked to a conjugating group G4, G5, G6, G7, G101, G102, G103, G105 or G106. 28. The conjugate of claim 27, wherein the conjugating group is attached to the 3' end of the sense strand. 29. A nucleic acid-protein complex, wherein the nucleic acid-protein complex comprises a double-stranded region of the siRNA duplex as described in any one of claims 1-16, and a nuclease; or, the nucleic acid-protein complex comprises an antisense strand of the double-stranded region of the siRNA duplex as described in any one of claims 1-16, and a nuclease. 30. The nucleic acid-protein complex of claim 29, wherein the nuclease is an AGO protein. 31. A pharmaceutical composition, characterized in that the pharmaceutical composition comprises the ingredients as described in any one of claims 1-16.The use of the siRNA duplex, the conjugate as described in any one of claims 17-28, or the nucleic acid-protein complex as described in claim 29 or 30, and a pharmaceutically acceptable carrier. Claims 21 / 22 pages 22 CN 121801914 A 32. Use of the siRNA duplex as described in any one of claims 1-16, the conjugate as described in any one of claims 17-28, the nucleic acid-protein complex as described in claim 29 or 30, or the pharmaceutical composition as described in claim 31 in the preparation of a medicament for the prevention and / or treatment of diseases related to INHBE gene expression. 33. Use of the siRNA duplex as described in any one of claims 1-16, the conjugate as described in any one of claims 17-28, the nucleic acid-protein complex as described in claim 29 or 30, or the pharmaceutical composition as described in claim 31 in the preparation of a medicament for the prevention and / or treatment of diabetes, obesity, including, for example, hyperlipidemia or dyslipidemia, insulin resistance or higher or altered insulin levels during fasting or metabolic challenges, hepatic steatosis or fatty liver disease, non-alcoholic steatohepatitis, elevated blood pressure and / or hypertension, metabolic syndrome, coronary artery disease and other atherosclerotic symptoms, and complications related to these diseases. Claims 22 / 22 pages 23 CN 121801914 A siRNA duplex, conjugate and application thereof targeting the expression of INHBE gene

[0001] This application claims priority to Chinese Patent Application 2025106087721 filed on 2025 / 5 / 12 and Chinese Patent Application 2025106147953 filed on 2025 / 5 / 13. This application cites the full text of the aforementioned Chinese patent application. Technical Field

[0002] This disclosure belongs to the field of biomedicine, specifically relating to siRNA duplexes and conjugates that target and regulate INHBE gene expression and their application in the prevention and treatment of metabolic-related diseases. Background Art

[0003] Nucleic acid drugs, especially oligonucleotide drugs, are widely used due to their simple synthesis and high activity. Oligonucleotide drugs typically include antisense oligonucleotides (ASO), small interfering RNA (siRNA), microRNA (miRNA), and nucleic acid aptamers.

[0004] Oligonucleotides are a class of short DNA or RNA molecules or oligomers. Oligonucleotides can bind to their respective complementary oligonucleotides, DNA, or RNA in a sequence-specific manner to form duplexes, or, although less common, in some cases, to form higher-order hybrids. Oligonucleotides can bind to complementary RNA chains in a sequence-specific manner, and after hybridization, they can induce RNase H cleavage of target RNA. In natural oligonucleotides, nucleotides are linked by phosphodiester bonds. Under physiological conditions, oligonucleotides…Nucleotides are particularly sensitive to nucleases. Therefore, in the preparation of oligonucleotide drugs, natural, unmodified, or unmodified oligonucleotides are easily and rapidly degraded in vivo, resulting in very limited activity and poor drug-likeness. Modifying oligonucleotides is an effective way to improve their activity, which can enhance their stability to nucleases, their affinity for RNA, and better promote endocytosis and tissue targeting, thereby effectively regulating the expression of target genes.

[0005] The basic structure of a nucleotide can generally be divided into four parts: base, ribose, phosphate backbone, and terminal. The modifications of these four parts can be exemplified as follows: 1) Base modification: mainly divided into three forms: purine modification, pyrimidine modification, and base substitution. Purine modifications include N6-methyladenosine, N1-methyladenosine, and 7-methylguanylic acid modifications; pyrimidine modifications include 3-methyluridine, 5-methyluridine, 5-methylcytosine, N4-acetylcytidine, pseudouridine, thiouridine, propynourishinidine, and dihydrouridine.

[0006] 2) Ribose modifications: mainly divided into modifications and substitutions of groups at specific positions on the ribose ring. Ribose modifications include, but are not limited to, 2'-position modifications, 4'-position modifications, 5'-position modifications, and isomer modifications. The most common 2'-position modifications of ribose are 2'-OMe (2'-methoxy) modification and 2'-F (2'-fluoro) modification. Compared with natural oligonucleotides, oligonucleotides modified with both 2'-OMe and 2'-F have higher Tm values, stronger serum stability, and better activity.

[0007] 3) Modification of the phosphate backbone: The main modification methods include, but are not limited to, modification of thiophosphates; modification via methyl phosphates, selenophosphates, methylboryl phosphates, dithiophosphates, and the replacement of bridging oxygen atoms in the phosphodiester bond linkage region with sulfur atoms; replacing the phosphate ester group between nucleosides entirely with a group that does not contain phosphorus atoms, such as replacing P atoms with C atoms, S atoms, and N atoms, thereby forming guanidine, S-methylthiourea, or nitrates, etc.

[0008] 4) Terminal modification: including but not limited to covalently linking specific groups at the 5' end and / or 3' end of the sense chain, phosphorylation modification at the 5' end of the antisense chain, etc.

[0009] Inhibin βE (INHBE) protein is a member of the transforming growth factor-β (TGF-β) superfamily. It is mainly specifically expressed in hepatocytes and is a secreted protein. After being cleaved, the INHBE protein dimers to form activin E, which may then inhibit lipolysis by activating specific signaling pathways (such as ALK7), thereby promoting fat accumulation.

[0010] Although there are currently drugs such as smegglutinin for the treatment of metabolic diseases such as diabetes and obesity,However, smegglutide has problems with poor compliance and significant side effects. Therefore, there is a need for alternative and combination therapies for patients with INHBE gene expression-related diseases.

[0011] Furthermore, based on research on INHBE in the art, INHBE gene expression-related diseases include not only diabetes and obesity, but also, for example, hyperlipidemia or dyslipidemia, insulin resistance or elevated or altered insulin levels during fasting or metabolic challenges, hepatic steatosis or fatty liver disease, non-alcoholic steatohepatitis, elevated blood pressure and / or hypertension, metabolic syndrome, coronary artery disease and other atherosclerotic symptoms, and complications related to these diseases. Therefore, oligonucleotide drugs that can be provided for the treatment of INHBE gene expression-related diseases are clinically needed. Summary of the Invention

[0012] This disclosure provides siRNAs, conjugates and their applications (e.g., applications in the preparation of drugs for treating metabolic diseases) that target and regulate INHBE gene expression. This disclosure screens out several siRNA modifiers that have significant inhibitory effects on INHBE gene expression by modifying the basic siRNA sequence, and provides corresponding siRNA conjugates.

[0013] The technical solutions of this disclosure include, but are not limited to: On one hand, this disclosure provides an siRNA duplex comprising an oligonucleotide duplex composed of a sense strand and an antisense strand paired together.

[0014] On the other hand, this disclosure provides a conjugate for reducing the expression of INHBE, comprising the above-mentioned siRNA duplex and a conjugate group connected thereto.

[0015] On the other hand, this disclosure provides a nucleic acid protein complex comprising the double-stranded region of the above-mentioned siRNA duplex or the antisense strand of the double-stranded region, and a nuclease.

[0016] On the other hand, this disclosure provides a recombinant vector comprising a nucleic acid molecule encoding the above-mentioned siRNA duplex.

[0017] In some embodiments, the vector backbone of the recombinant vector is selected from recombinant viroid-derived circular RNA vectors, tRNA, rRNA scaffolds, and chimeric tRNA / pre-miRNA vectors.

[0018] On the other hand, this disclosure provides a recombinant cell that synthesizes and secretes the above-mentioned siRNA duplex.

[0019] In some embodiments, the recombinant cells are selected from *Pseudomonas thiophanate-methyl* and *Corynebacterium glutamicum* deficient in ribonuclease III.

[0020] On the other hand, this disclosure provides a method for preparing siRNA duplexes, comprising culturing the above-mentioned recombinant cells, or chemical synthesis.

[0021] On the other hand, this disclosure provides a pharmaceutical composition comprising the above-mentioned siRNA duplexes, the above-mentioned conjugates, or the above-mentioned nucleic acid-protein complexes, and a pharmaceutically acceptable carrier.

[0022] On the other hand, this disclosure provides a kit comprising a kit A, the kit A comprising...One or more of the above-mentioned siRNA, conjugate, or pharmaceutical composition.

[0023] In some embodiments, the kit further includes a box B containing one or more of the following: (1) other drugs that reduce INHBE gene expression or compositions containing such drugs; (2) one or more of the group consisting of insulin, glucagon-like peptide-1 agonists, sulfonylureas, seglinide, biguanides, thiazolidinediones, α-glucosidase inhibitors, SGLT2 inhibitors, DPP-4 inhibitors, and HMG-CoA reductase inhibitors.

[0024] On the other hand, this disclosure provides a method for inhibiting INHBE gene expression or inhibiting INHBE replication, comprising contacting one or more of the above-mentioned siRNA duplexes, conjugates, pharmaceutical compositions, and kits with target cells.

[0025] In some embodiments, the method is for non-diagnostic or non-therapeutic purposes.

[0026] In some embodiments, the method is in vivo or in vitro.

[0027] On the other hand, this disclosure provides the use of the above-described siRNA duplex, conjugate, recombinant vector, recombinant cell, or pharmaceutical composition in the preparation of a medicament for the prevention and / or treatment of INHBE gene expression-related diseases.

[0028] The INHBE gene expression-related diseases are selected from diseases caused by INHBE protein overexpression, pathogenic mutations in the INHBE gene, abnormal metabolism of the INHBE protein, or abnormal interaction between INHBE and another substance.

[0029] On the other hand, this disclosure provides the above-described siRNA duplex, the above-described conjugate, the above-described pharmaceutical composition, or the above-described kit for the treatment and / or prevention of INHBE gene expression-related diseases.

[0030] On the other hand, this disclosure provides a method for the treatment and / or prevention of INHBE gene expression-related diseases, comprising administering an effective amount of the above-described siRNA duplex, the above-described conjugate, or the above-described pharmaceutical composition to a subject in need, or administering it to the subject in need using the above-described kit.

[0031] On the other hand, this disclosure provides the above-mentioned siRNA double strand, the above-mentioned conjugate, the above-mentioned pharmaceutical composition, or the above-mentioned kit for treating metabolic disorders and cardiovascular and cerebrovascular diseases.

[0032] On the other hand, this disclosure provides a method for treating metabolic disorders and cardiovascular and cerebrovascular diseases, comprising administering an effective amount of the above-mentioned siRNA double strand, the above-mentioned nucleic acid protein composition, or the above-mentioned pharmaceutical composition to a subject in need, or administering it to the subject in need using the above-mentioned kit.

[0033] Those skilled in the art will recognize that the INHBE gene expression-related diseases of this disclosure include, but are not limited to:Type 2 diabetes, hyperlipidemia or dyslipidemia (high or altered circulating levels of low-density lipoprotein cholesterol (LDL-C), triglycerides, very low-density lipoprotein cholesterol (VLDL-C), apolipoprotein B or other lipid fractions), obesity (especially abdominal obesity), lipodystrophy (such as the inability to deposit fat locally in fat deposits (partial lipodystrophy) or the inability to deposit fat throughout the body (lipoatrophy)), insulin resistance or higher or altered insulin levels during fasting or metabolic challenges, hepatic steatosis or fatty liver disease and its complications (such as, for example, cirrhosis, fibrosis or liver inflammation), non-alcoholic steatohepatitis, other types of liver inflammation, liver enzyme levels or liver injury, higher or altered or elevated other markers of inflammation or steatosis in the liver, elevated blood pressure and / or hypertension, elevated blood glucose or blood glucose or hyperglycemia, metabolic syndrome, coronary artery disease and other atherosclerotic conditions, and complications of each of the above diseases or conditions, as well as any other diseases associated with INHBE gene expression and other unidentified related conditions, pathologies or syndromes.

[0034] Based on common knowledge in the art, the above preferred conditions can be combined arbitrarily to obtain various preferred embodiments of the present disclosure.

[0035] The effects of the present disclosure are at least as follows: (1) The siRNA base sequence of the present disclosure has a significant inhibitory effect on the INHBE gene, with an inhibition rate of more than 50%.

[0036] (2) The siRNA modified by the modified template method has an inhibition rate of more than 70%. Specification 3 / 91 pages 26 CN 121801914 A Detailed Description

[0037] In order to make the present disclosure easier to understand, certain terms are first defined. In addition, it should be noted that whenever a value or a range of values ​​for a parameter is enumerated, the purpose is to indicate that the intermediate values ​​and ranges of these referenced values ​​are also intended to be part of the present disclosure.

[0038] The articles “a” and “an” as used herein refer to one or more (i.e., at least one) grammatical objects of the article. By way of example, “an element” refers to one or more elements, such as multiple elements.

[0039] The term “including” as used herein refers to the phrase “including but not limited to” and may be used interchangeably with it.

[0040] The term “or” as used herein refers to the term “and / or” and may be used interchangeably with it unless the context clearly indicates otherwise.

[0041] As used herein, the terms “about” or “approximately” applied to one or more target values ​​refer to values ​​similar to the reference value. In some embodiments, unless otherwise stated or otherwise apparent from the context, the terms “approximately” or “approximately” are used interchangeably with the reference value.“Approximately” means a range of values ​​falling within 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less of the reference value in any direction (unless such a number would exceed 100% of the possible value).

[0042] As used herein, “INHBE” refers to the repressin subunit βE gene or protein, and those skilled in the art can readily distinguish whether INHBE refers to a gene or a protein based on the context.

[0043] The term “INHBE gene” can refer to the wild-type INHBE gene or a mutant INHBE gene with sequence variations. Many sequence variations in the INHBE gene have been identified and can be found, for example, in NCBI dbSNP and UniProt (see, for example, ncbi.nlm.nih.gov / snp).

[0044] “G”, “C”, “A” and “U” each typically represent a nucleotide containing guanine, cytosine, adenine and uracil as bases, respectively. “T” and “dT” are used interchangeably herein and refer to a deoxyribonucleotide in which the nucleobase is thymine such as deoxyribothymine, 2'-deoxythymidine or thymidine. However, it should be understood that the terms “ribonucleotide” or “nucleotide” or “deoxyribonucleotide” can also refer to a modified nucleotide (as further detailed below) or an alternative substitution moiety. Those skilled in the art will readily appreciate that guanine, cytosine, adenine and uracil can be substituted with other moieties without substantially altering the base-pairing properties of an oligonucleotide (including a nucleotide having such a substitution moiety). For example, and not limited to, a nucleotide containing inosine as its base can pair with a nucleotide containing adenine, cytosine or uracil. Therefore, nucleotides containing uracil, guanine, or adenine can be substituted in the nucleotide sequence of this disclosure with a nucleotide containing, for example, inosine. Sequences containing such substitutions are applicable to, but are not limited to, double-stranded ribonucleic acids, double-stranded ribonucleic acid modifications, double-stranded ribonucleic acid conjugates, pharmaceutical compositions, and methods of this disclosure.

[0045] The terms “complementary,” “fully complementary,” and “substantially complementary” can be used herein to refer to base pairing between the sense and antisense strands of siRNA, or between the antisense strand of siRNA and the target sequence, as can be understood from the context in which they are used. In some embodiments herein, the first nucleotide sequence can be considered complementary to the second nucleotide sequence if the first nucleotide sequence exhibits sequence complementarity to the second nucleotide sequence to at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%.The dinucleotide sequences are complementary. In one exemplary embodiment, 18 of the 20 nucleotide bases of the first nucleotide sequence pair with the corresponding region of the second nucleotide sequence, achieving 90% complementarity.

[0046] The terms “double-stranded ribonucleic acid,” “double-stranded RNA (dsRNA) molecule,” “dsRNA,” and “ribonucleic acid duplex” can be used interchangeably in this specification (page 4 / 91, CN 121801914 A), specifically referring to a complex of ribonucleic acid molecules having a double-stranded structure containing two antiparallel, complementary, or substantially complementary nucleic acid strands, with “sense” and “antisense” orientations relative to a target gene, such as the INHBE gene. In some embodiments, the double-stranded ribonucleic acid (dsRNA) triggers the degradation of target RNA, such as mRNA, through a post-transcriptional gene silencing mechanism (referred to herein as RNA interference or RNAi). In this document, in some cases, “siRNA duplex” also typically refers to the technical meaning implied by the above definition.

[0047] As is well known in the art, the terms “siRNA duplex,” “double-stranded RNAi agent,” “RNAi agent,” “small interfering RNA,” or “siRNA” refer to small interfering RNA (RNAi) molecules. It is a class of double-stranded RNA molecules, also known in the art as short interfering RNA or silent RNA. siRNA typically comprises a sense strand (also called a guest strand) and an antisense strand (also called a leader strand), each strand being 17 to 30 nucleotides in length, typically 19 to 25 nucleotides in length, wherein the antisense strand is complementary to the target nucleic acid (suitably a mature mRNA sequence) (e.g., at least 95% complementary, e.g., fully complementary), and the sense strand is complementary to the antisense strand such that the sense and antisense strands form a duplex or duplex region. The sense and antisense strands of siRNA may form a blunt-ended duplex, or may form a duplex including a 3′ overhang, which may be, for example, 1, 2, or 3 nucleotides in length, similar to the product produced by Dicer, which can form RISC substrates in vivo. Efficient extended forms of Dicer substrates have been described in US 8349809 and US 8513207, which are incorporated herein by reference. In some embodiments, both the sense and antisense strands have a 3′ overhang of 2 nucleotides. Thus, the length of the double-stranded region can be, for example, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides, such as 19, 20, 21, 22, or 23 nucleotides in length.

[0048] Furthermore, in this document, “siRNA” also refers to “base sequence” in some cases. In this document, “base sequence” specifically refers to a double-stranded siRNA in which each nucleotide is an unmodified nucleotide.The term "siRNA motif" appears throughout the text. Therefore, in this text, "siRNA," "basic sequence," "motif," and "siRNA motif" can be used interchangeably, and their meanings also include the corresponding nucleotide sequence of the siRNA double strand they refer to. In this text, those skilled in the art can clearly understand the precise technical meaning they refer to based on the context. Furthermore, the 5' terminal nucleotide of the antisense strand of the motif may be linked to a 5' phosphate group or a 5' phosphate-derived group, or may not be linked to a 5' phosphate group or a 5' phosphate-derived group.

[0049] In this text, "siRNA modifier" refers to a double-stranded ribonucleic acid containing at least one modified nucleotide, and in some cases, it also appears as "double-stranded ribonucleic acid modifier." In this text, the siRNA motif is modified in different ways to prepare the corresponding siRNA modifier. For example, in some embodiments, the motif is modified in an alternating manner to obtain alternatingly modified siRNA modifiers. In other embodiments, the motif is modified using a specific modification template to obtain a siRNA modified with that specific modification template. In still other embodiments, the motif is modified using the off-target modification method described herein to obtain an off-target modified siRNA. In some cases, multiple different modification methods can be used simultaneously to modify the same siRNA motif to obtain corresponding siRNA modified products with multiple modification methods.

[0050] In this document, "siRNA conjugate" refers to a double-stranded ribonucleic acid conjugate or a conjugate of a double-stranded ribonucleic acid modified product obtained by attaching a conjugate group to a double-stranded ribonucleic acid, a double-stranded ribonucleic acid modified product. Preferably, "siRNA conjugate" refers to a conjugate of a double-stranded ribonucleic acid modified product.

[0051] In some instances herein, “siRNA” refers not only to the unmodified siRNA double strand (or siRNA motif) described above, but may also refer to its corresponding siRNA modifier and / or siRNA conjugate. For example, in contexts relating to treatment methods, therapeutic agents, etc., siRNA generally refers to at least one of siRNA motifs, siRNA modifiers, and / or siRNA conjugates. The specific technical meaning will be clear to those skilled in the art in the context. Specification 5 / 91 pages 28 CN 121801914 A

[0052] The term “antisense strand” refers to a strand of double-stranded ribonucleic acid (e.g., the siRNA double strand herein) that includes a region substantially complementary to the target sequence. When used herein, the term “complementary region” refers to a region on the antisense strand that is substantially complementary to a sequence (e.g., the target sequence) as defined herein. When the complementary region is not perfectly complementary to the target sequence, mismatches can occur within the molecule.Or terminal regions. Typically, the most permissible mismatches are in terminal regions, for example, within 5, 4, 3, 2, or 1 nucleotides at the 5' and / or 3' ends.

[0053] The term "sense strand" as used herein refers to a strand of double-stranded ribonucleic acid that includes a region substantially complementary to the region of the antisense strand (as defined herein).

[0054] The term "alternating modification" refers to a modification in which nucleotides are modified with 2'-methoxy (2'-OMe) and 2'-fluoro (2'-F) respectively, according to the nucleotide sequence of the double-stranded ribonucleic acid. For example, for the antisense strand of siRNA, odd-numbered positions (i.e., positions 1, 3, 5, 7, 11, 13, 15, 17, 19, 21, and 23) are modified with 2'-methoxy, and even-numbered positions (i.e., positions 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22) are modified with 2'-fluorination. For the sense strand complementary to this antisense strand, the corresponding position of the antisense strand modified with 2'-methoxy is modified with 2'-fluorination; at the position on the antisense strand where 2'-fluorination is used, the complementary pairing position on the sense strand is modified with 2'-methoxy.

[0055] For RNA interference (RNAi), the inhibition of the target gene is achieved by loading the antisense strand of siRNA onto the AGO2 protein and forming a silencing complex (RISC) to cleave the transcript mRNA of the gene. Loading of the silencing complex (RISC) requires phosphorylation (5'-phosphate) of the 5' end of the antisense strand. 5'-phosphate can occur naturally within the cell by cleaving and polyadenylation of factor I subunit 1 (Clp1), or it can be achieved through chemical synthesis. The terms "natural 5'-phosphate" or "simple, direct 5'-phosphate" refer to 5'-phosphate of the siRNA antisense strand occurring in an intracellular environment, rather than through chemical synthesis.

[0056] In this document, "conjugation group" is a GalNAc derivative attached to an oligonucleotide. In some cases, the conjugation group includes a targeting group (also referred to as a ligand), and optionally also includes a linker, such as a GalNAc derivative attached to the oligonucleotide via a linker (e.g., a divalent, trivalent, or tetravalent branched linker arm), or, for example, a GalNAc derivative attached to the oligonucleotide via a monovalent linker arm. In most cases, both "ligand" and "conjugation group" have meanings known in the art.

[0057] The term “inhibition” as used herein may be used interchangeably with “reduction,” “silence,” “downregulation,” “suppression,” and other similar terms, and includes any level of inhibition. In some instances herein, “regulation” refers to “inhibition,” and those skilled in the art will clearly understand its specific meaning from the context.

[0058] As used herein, the phrase “inhibit INHBE expression” includes inhibiting the expression of any INHBE gene (e.g., mouse INHBE gene, rat INHBE gene, monkey INHBE gene, or human INHBE gene) and variants (e.g., naturally occurring variants) or mutants of the INHBE gene. Therefore, the INHBE gene can be a wild-type INHBE gene, a mutant INHBE gene, or, in the case of genetically manipulated cells, cell groups, or organisms, a transgenic INHBE gene.

[0059] “Inhibition of INHBE gene expression” includes inhibition of the INHBE gene at any level, such as at least partial inhibition of INHBE gene expression, such as inhibition of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 8%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%.

[0060] INHBE gene expression can be assessed based on the level of any variable associated with INHBE gene expression, such as INHBE mRNA level or INHBE protein level. The inhibition can be assessed by a reduction in the absolute or relative level of one or more of these variables compared to a control level. The control level can be any type of control level used in the art, such as the baseline level before administration or the level determined from a similar untreated or controlled (e.g., buffer-only control or inert agent control) subject, cell, or sample.

[0061] In this document, in some cases, “regulation” can mean the same as “inhibition”; accordingly, “regulation of INHBE gene expression” can mean “inhibition of INHBE gene expression”. The specific technical meaning will be clear to those skilled in the art in the context.

[0062] As used herein, “patient” or “subject” is intended to include human or non-human animals, preferably mammals, such as monkeys. Preferably, the subject or patient is a human.

[0063] As used herein, “INHBE gene expression-related disease” is intended to include any disease related to the INHBE gene or protein. Such disease can be caused, for example, by overproduction of the INHBE protein, by mutation of the INHBE gene, by abnormal cleavage of the INHBE protein, or by abnormal interactions between INHBE and other proteins or other endogenous or exogenous substances. ExampleINHBE-related diseases include metabolic conditions associated with body fat distribution, including but not limited to: type 2 diabetes, hyperlipidemia or dyslipidemia (high or altered circulating levels of low-density lipoprotein cholesterol (LDL-C), triglycerides, very low-density lipoprotein cholesterol (VLDL-C), apolipoprotein B, or other lipid fractions), obesity (especially abdominal obesity), lipodystrophy (such as the inability to deposit fat locally in fat deposits (partial lipodystrophy) or the inability to deposit fat throughout the body (lipomatosis)), insulin resistance or higher or altered insulin levels during fasting or metabolic challenges, hepatic steatosis or fatty liver disease and its complications (e.g., cirrhosis, fibrosis, or liver inflammation), non-alcoholic steatohepatitis, other types of liver inflammation, liver enzyme levels or liver damage, higher or altered levels or other markers of inflammation or steatosis in the liver, higher and / or hypertension, higher or hyperglycemia or blood glucose, metabolic syndrome, coronary artery disease and other atherosclerotic conditions, and complications of each of the above conditions.

[0064] As used herein, a “therapeutic effective amount” is intended to include an amount of RNAi agent sufficient to achieve treatment of an INHBE-related disease (e.g., by attenuating, improving, or maintaining the existing disease or symptoms of one or more diseases) when administered to a patient. This “therapeutic effective amount” can vary depending on the RNAi agent, how it is administered, the disease and its severity, and medical history, age, weight, family history, genetic makeup, stage of the pathological process mediated by INHBE expression, type of prior or concomitant treatment (if any), and other individual characteristics of the patient to be treated.

[0065] As used herein, a “preventive effective amount” refers to an amount of RNAi agent sufficient to prevent or improve the disease or one or more symptoms of the disease when administered to a subject who has not yet experienced or exhibited symptoms of an INHBE-related disease but may be susceptible to it. Improving the disease includes slowing its progression or reducing the severity of subsequent disease development. The “preventative effective dose” can vary depending on the RNAi agent, how the agent is administered, the risk level of the disease, and medical history, age, weight, family history, genetic composition, type of prior or concomitant treatment (if any), and other individual characteristics of the patient to be treated.

[0066] The “therapeutic effective dose” or “preventative effective dose” also includes the amount of RNAi agent that produces a desired local or systemic effect at a reasonable benefit / risk ratio applicable to any treatment. The RNAi agent used in the methods of this disclosure can be administered in an amount sufficient to produce a reasonable benefit / risk ratio applicable to such treatment.

[0067] As used herein, the term “sample” includes similar fluids, cells, or tissues isolated from the body of a subject.And a collection of fluids, cells, or tissues present in the subject's body. Examples of biological fluids include blood, serum and serous fluid, plasma, cerebrospinal fluid, ocular fluid, lymph, urine, saliva, etc. Tissue samples may include samples from tissues, organs, or local areas. For example, a sample may be derived from a specific organ, part of an organ, or fluids or cells within those organs. In some embodiments, a sample may be derived from the liver (e.g., the entire liver or a segment of the liver, or certain types of cells in the liver, such as hepatocytes). In a preferred embodiment, "sample derived from the subject" means blood or plasma drawn from the subject's specification page 7 / 91 30 CN 121801914 A. In other embodiments, "sample derived from the subject" means liver tissue (or a subcomponent thereof) derived from the subject.

[0068] In this document, unless otherwise specified, any nucleotide position of any strand of any siRNA motif, siRNA modification, siRNA conjugate, siRNA duplex, etc., refers to the 5' to 3' orientation.

[0069] In one aspect, this disclosure provides a siRNA duplex that targets and regulates the expression of the INHBE gene, comprising a sense strand and an antisense strand forming an inverse complementary double-stranded region, wherein the antisense strand comprises at least 15, 16, 17, 18, or 19 consecutive nucleotides complementary to a target sequence as shown in SEQ ID NO: 907 (UUGGAGUGAAGAGACCAAGAUGAAGUUUCCCAG), or the antisense strand comprises at least 15, 16, 17, 18, or 19 consecutive nucleotide fragments or modified fragments thereof from any of the sequences shown in SEQ ID NO: 13-24, 134-236, 238-240, 252-260.

[0070] In some embodiments, the target sequence is derived from the transcript of the inhibin subunit βE (INHBE) with accession number NM_031479.5 in the NCBI database.

[0071] In some embodiments, the antisense strand comprises the sequence shown in SEQ ID NO: 906 (UCAUCUUGGUCUC). For example, the nucleotide sequence of the antisense strand is as described in any one of SEQ ID NO: 13-16 and 18-23.

[0072] In some embodiments, the antisense strand comprises at least 15, 16, 17, 18, or 19 consecutive nucleotides complementary to the target sequence shown in SEQ ID NO: 907. For example, the nucleotide sequence of the antisense strand is as described in any one of SEQ ID NO: 13-16 and 18-23.

[0073] In some embodiments, the length of the anticomplementary double-stranded region is 17-21 bp, for example, 20 or 21 bp.

[0074] In some embodiments, the sense strand comprises at least 17, 18, or 19 consecutive nucleotide fragments or modified fragments thereof, as shown in any of SEQ ID NO: 1-12, 25-127, 129-131, 243-251.

[0075] In some embodiments, the sense strand comprises the sequence shown in SEQ ID NO: 905 (GAGACCAAGAUGA).

[0076] In some embodiments, the sense strand and antisense strand each independently comprise 19-23 nucleotides; preferably, the sense strand comprises 19-21 nucleotides, and the antisense strand comprises 21-23 nucleotides.

[0077] In some embodiments, the siRNA duplex is siRNA for inhibiting INHBE gene expression.

[0078] In some embodiments, the siRNA duplex comprises any one or a combination of at least two of any oligonucleotide duplexes selected from the following positive and negative strand pairings: the positive strand having the sequence shown in SEQ ID NO: 1, or a modified sequence of the sequence; and the negative strand having the sequence shown in SEQ ID NO: 13, or a modified sequence of the sequence; the positive strand having the sequence shown in SEQ ID NO: 2, or a modified sequence of the sequence; and the negative strand having the sequence shown in SEQ ID NO: 14, or a modified sequence of the sequence; the positive strand having the sequence shown in SEQ ID NO: 3, or a modified sequence of the sequence; and the negative strand having the sequence shown in SEQ ID NO: 15, or a modified sequence of the sequence; the positive strand having the sequence shown in SEQ ID NO: 4, or a modified sequence of the sequence; and the negative strand having the sequence shown in SEQ ID NO: 16, or a modified sequence of the sequence or a fragment thereof; the positive strand having the sequence shown in SEQ ID NO: 16, or a modified sequence of the sequence or a fragment thereof; the positive strand having the sequence shown in SEQ ID NO: 14, or a modified sequence of the ... The sequence shown in SEQ ID NO: 5, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 17, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 6, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 18, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 7, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 19, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 8, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 19, or a modified sequence of the sequence;The sequence shown in SEQ ID NO: 20, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 9, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 21, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 10, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 22, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 11, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 23, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 12, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 24, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 25, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 134, or a modified sequence of the sequence; The positive chain has a sequence as shown in SEQ ID NO: 26, or a modified sequence of the sequence; and the negative chain has a sequence as shown in SEQ ID NO: 135, or a modified sequence of the sequence; The positive chain has a sequence as shown in SEQ ID NO: 27, or a modified sequence of the sequence; and the negative chain has a sequence as shown in SEQ ID NO: 136, or a modified sequence of the sequence; The positive chain has a sequence as shown in SEQ ID NO: 28, or a modified sequence of the sequence; and the negative chain has a sequence as shown in SEQ ID NO: 137, or a modified sequence of the sequence; The positive chain has a sequence as shown in SEQ ID NO: 29, or a modified sequence of the sequence; and the negative chain has a sequence as shown in SEQ ID NO: 138, or a modified sequence of the sequence; The positive chain has a sequence as shown in SEQ ID NO: 30, or a modified sequence of the sequence; and the negative chain has a sequence as shown in SEQ ID NO: 139, or a modified sequence of the sequence; The positive chain has a sequence as shown in SEQ ID NO: The sequence shown in SEQ ID NO: 31, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 140, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 32, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 141, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 32, or a modified sequence of the sequence;The sequence shown in SEQ ID NO: 33, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 142, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 34, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 143, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 35, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 144, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 36, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 145, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 37, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 146, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: The sequence shown in SEQ ID NO: 38, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 147, or a modified sequence of the sequence; Specification 9 / 91 Page 32 CN 121801914 A The positive chain having the sequence shown in SEQ ID NO: 39, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 148, or a modified sequence of the sequence; The positive chain having the sequence shown in SEQ ID NO: 40, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 149, or a modified sequence of the sequence; The positive chain having the sequence shown in SEQ ID NO: 41, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 150, or a modified sequence of the sequence; The positive chain having the sequence shown in SEQ ID NO: 42, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: The sequence shown in SEQ ID NO: 151, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 43, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 152, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 44, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 153, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 152, or a modified sequence of the sequence;The sequence shown in SEQ ID NO: 45, or a modified sequence thereof; and the antisense chain having the sequence shown in SEQ ID NO: 154, or a modified sequence thereof; the positive chain having the sequence shown in SEQ ID NO: 46, or a modified sequence thereof; and the antisense chain having the sequence shown in SEQ ID NO: 155, or a modified sequence thereof; the positive chain having the sequence shown in SEQ ID NO: 47, or a modified sequence thereof; and the antisense chain having the sequence shown in SEQ ID NO: 156, or a modified sequence thereof; the positive chain having the sequence shown in SEQ ID NO: 48, or a modified sequence thereof; and the antisense chain having the sequence shown in SEQ ID NO: 157, or a modified sequence thereof; the positive chain having the sequence shown in SEQ ID NO: 49, or a modified sequence thereof; and the antisense chain having the sequence shown in SEQ ID NO: 158, or a modified sequence thereof; the positive chain having the sequence shown in SEQ ID NO: 15 ... The sequence shown in SEQ ID NO: 50, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 159, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 51, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 160, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 52, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 161, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 53, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 162, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 54, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 163, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: The sequence shown in SEQ ID NO: 55, or a modified sequence thereof; and the antisense chain having the sequence shown in SEQ ID NO: 164, or a modified sequence thereof; the positive chain having the sequence shown in SEQ ID NO: 56, or a modified sequence thereof; and the antisense chain having the sequence shown in SEQ ID NO: 165, or a modified sequence thereof; the positive chain having the sequence shown in SEQ ID NO: 57, or a modified sequence thereof; and the antisense chain having the sequence shown in SEQ ID NO: 57, or a modified sequence thereof;The sequence shown in SEQ ID NO: 166, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 58, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 167, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 59, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 168, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 60, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 169, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 61, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 170, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: The sequence shown in SEQ ID NO: 62, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 171, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 63, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 172, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 64, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 173, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 65, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 174, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 66, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 175, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 66, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 175, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 64, or a modified sequence of the sequence; The sequence shown in SEQ ID NO: 67, or a modified sequence thereof; and the antisense chain having the sequence shown in SEQ ID NO: 176, or a modified sequence thereof; the positive chain having the sequence shown in SEQ ID NO: 68, or a modified sequence thereof; and the antisense chain having the sequence shown in SEQ ID NO: 177, or a modified sequence thereof; the positive chain having the sequence shown in SEQ ID NO: 69, or a modified sequence thereof; and the antisense chain having the sequence shown in SEQ ID NO: 69, or a modified sequence thereof;The sequence shown in SEQ ID NO: 178, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 70, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 179, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 71, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 180, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 72, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 181, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 73, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 182, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 74, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: The sequence shown in SEQ ID NO: 183, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 75, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 184, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 76, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 185, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 77, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 186, or a modified sequence of the sequence; Specification 11 / 91 Page 34 CN 121801914 A The positive chain has the sequence shown in SEQ ID NO: 78, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 187, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: The sequence shown in SEQ ID NO: 79, or a modified sequence thereof; and the antisense chain having the sequence shown in SEQ ID NO: 188, or a modified sequence thereof; the positive chain having the sequence shown in SEQ ID NO: 80, or a modified sequence thereof; and the antisense chain having the sequence shown in SEQ ID NO: 189, or a modified sequence thereof; the positive chain having the sequence shown in SEQ ID NO: 81, or a modified sequence thereof; and the antisense chain having the sequence shown in SEQ ID NO: 79, or a modified sequence thereof;The sequence shown in SEQ ID NO: 190, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 82, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 191, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 83, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 192, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 84, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 193, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 85, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 194, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 86, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 194, or a modified sequence of the sequence; The sequence shown in SEQ ID NO: 195, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 87, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 196, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 88, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 197, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 89, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 198, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 90, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 199, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 91, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 90, or a modified sequence of the sequence; The sequence shown in SEQ ID NO: 200, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 92, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 201, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 93, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 202, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO:The sequence shown in SEQ ID NO: 94, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 203, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 95, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 204, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 96, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 205, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 97, or a modified sequence of the sequence; and the positive chain having the sequence shown in SEQ ID NO: 206, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 98, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 99, or a modified sequence of the sequence; The sequence shown in SEQ ID NO: 207, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 99, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 208, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 100, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 209, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 101, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 210, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 102, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 211, or a modified sequence of the sequence; the positive chain has the sequence shown in SEQ ID NO: 103, or a modified sequence of the sequence; and the negative chain has the sequence shown in SEQ ID NO: 208, or a modified sequence of the sequence; The sequence shown in SEQ ID NO: 212, or a modified sequence thereof; the positive chain has the sequence shown in SEQ ID NO: 104, or a modified sequence thereof; and the negative chain has the sequence shown in SEQ ID NO: 213, or a modified sequence thereof; the positive chain has the sequence shown in SEQ ID NO: 105, or a modified sequence thereof; and the negative chain has the sequence shown in SEQ ID NO: 214, or a modified sequence thereof; the positive chain has the sequence shown in SEQ ID NO: 212, or a modified sequence thereof.The sequence shown in SEQ ID NO: 106, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 215, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 107, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 216, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 108, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 217, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 109, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 218, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 110, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 219, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 108, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 109 ... The sequence shown in SEQ ID NO: 111, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 220, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 112, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 221, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 113, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 222, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 114, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 223, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 115, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 224, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: The sequence shown in SEQ ID NO: 116, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 225, or a modified sequence of the sequence; Specification 13 / 91 Page 36 CN 121801914 A The positive chain having the sequence shown in SEQ ID NO: 117, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 226, or a modified sequence of the sequence; The positive chain having the sequence shown in SEQ ID NO: 117, or a modified sequence of the sequence;The sequence shown in SEQ ID NO: 118, or a modified sequence thereof; and the antisense chain having the sequence shown in SEQ ID NO: 227, or a modified sequence thereof; the positive chain having the sequence shown in SEQ ID NO: 119, or a modified sequence thereof; and the antisense chain having the sequence shown in SEQ ID NO: 228, or a modified sequence thereof; the positive chain having the sequence shown in SEQ ID NO: 120, or a modified sequence thereof; and the antisense chain having the sequence shown in SEQ ID NO: 229, or a modified sequence thereof; the positive chain having the sequence shown in SEQ ID NO: 121, or a modified sequence thereof; and the antisense chain having the sequence shown in SEQ ID NO: 230, or a modified sequence thereof; the positive chain having the sequence shown in SEQ ID NO: 122, or a modified sequence thereof; and the antisense chain having the sequence shown in SEQ ID NO: 231 ... The sequence shown in SEQ ID NO: 123, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 232, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 124, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 233, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 125, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 234, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 126, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 235, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 127, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 236, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: The sequence shown in SEQ ID NO: 129, or a modified sequence thereof; and the antisense chain having the sequence shown in SEQ ID NO: 238, or a modified sequence thereof; the positive chain having the sequence shown in SEQ ID NO: 130, or a modified sequence thereof; and the antisense chain having the sequence shown in SEQ ID NO: 239, or a modified sequence thereof; the positive chain having the sequence shown in SEQ ID NO: 131, or a modified sequence thereof; and theThe antisense chain has a sequence as shown in SEQ ID NO: 240, or a modified sequence of said sequence; the positive chain has a sequence as shown in SEQ ID NO: 243, or a modified sequence of said sequence; and the antisense chain has a sequence as shown in SEQ ID NO: 252, or a modified sequence of said sequence; the positive chain has a sequence as shown in SEQ ID NO: 244, or a modified sequence of said sequence; and the antisense chain has a sequence as shown in SEQ ID NO: 253, or a modified sequence of said sequence; the positive chain has a sequence as shown in SEQ ID NO: 245, or a modified sequence of said sequence; and the antisense chain has a sequence as shown in SEQ ID NO: 254, or a modified sequence of said sequence; the positive chain has a sequence as shown in SEQ ID NO: 246, or a modified sequence of said sequence; and the antisense chain has a sequence as shown in SEQ ID NO: 255, or a modified sequence of said sequence; the positive chain has a sequence as shown in SEQ ID NO: The sequence shown in SEQ ID NO: 247, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 256, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 248, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 257, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 249, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 258, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 250, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: 259, or a modified sequence of the sequence; the positive chain having the sequence shown in SEQ ID NO: 251, or a modified sequence of the sequence; and the antisense chain having the sequence shown in SEQ ID NO: The sequence shown in SEQ ID NO: 260, or a modified sequence of the sequence.

[0079] In some embodiments, the sense strand differs from any of the sequences in SEQ ID NO: 1-12, 25-127, 129-131, 243-251 by 1-3 nucleotides.

[0080] In some embodiments, the antisense strand differs from any of the sequences in SEQ ID NO: 13-24, 134-236, 238-240, 252-260 by 1-3 nucleotides.

[0081] In some preferred embodiments, the nucleotide sequence of the sense strand is as shown in SEQ ID NO:As shown in any one of 1 to 12, and the nucleotide sequences of their corresponding antisense strands are shown in SEQ ID NO: 13 to 24, respectively.

[0082] In some embodiments, the number of nucleotides in the positive strand is the same as or different from the number of nucleotides in the antisense strand.

[0083] In some embodiments, the positive strand has 19 nucleotides, and the antisense strand has 19 nucleotides.

[0084] In some embodiments, the positive strand has 20 nucleotides, and the antisense strand has 19 nucleotides.

[0085] In some embodiments, the positive strand has 20 nucleotides, and the antisense strand has 20 nucleotides.

[0086] In some embodiments, the positive strand has 19 nucleotides, and the antisense strand has 20 nucleotides.

[0087] In some embodiments, the positive strand has 19 nucleotides, and the antisense strand has 21 nucleotides.

[0088] In some embodiments, the positive strand has 20 nucleotides, and the antisense strand has 21 nucleotides.

[0089] In some embodiments, the sense strand has 21 nucleotides and the antisense strand has 21 nucleotides.

[0090] In some embodiments, the sense strand has 19 nucleotides and the antisense strand has 22 nucleotides.

[0091] In some embodiments, the sense strand has 20 nucleotides and the antisense strand has 22 nucleotides.

[0092] In some embodiments, the sense strand has 21 nucleotides and the antisense strand has 22 nucleotides.

[0093] In some embodiments, the sense strand has 19 nucleotides and the antisense strand has 23 nucleotides.

[0094] In some embodiments, the sense strand has 20 nucleotides and the antisense strand has 23 nucleotides.

[0095] In some embodiments, the sense strand has 21 nucleotides and the antisense strand has 23 nucleotides.

[0096] In some embodiments, the sense strand has 23 nucleotides and the antisense strand has 23 nucleotides.

[0097] In some embodiments, the sense strand and antisense strand each independently comprise at least one modified nucleotide.

[0098] In some embodiments, the at least one modified nucleotide is selected from any or a combination of at least two of the following: deoxy-nucleotides, 3'-terminal deoxy-thymidine (dT) nucleotides, 2'-O-methyl modified nucleotides, 2'-fluorine modified nucleotides, 2'-deoxy-modified nucleotides, locked nucleotides, unlocked nucleotides, non-locked nucleotides, configuration-restricted nucleotides, restricted ethyl nucleotides, base-free nucleotides, 2'-amino-modified nucleotides, 2'-O-allyl-modified nucleotides, 2'-C-alkyl-modified nucleotides, 2'-hydroxy-modified nucleotides, 2'-methoxyethyl-modified nucleotides,2'-O-alkyl-modified nucleotides, morpholinonucleotides, aminophosphates, nucleotides containing non-natural bases, tetrahydropyran-modified nucleotides, 1,5-anhydrohexyl-modified nucleotides, cyclohexenyl-modified nucleotides, nucleotides containing thiophosphate groups, nucleotides containing methylphosphate groups, nucleotides containing 5'-phosphates, and nucleotides containing 5'-phosphates.

[0099] In some embodiments, at least one strand contains a 3' overhang of at least one nucleotide.

[0100] In some embodiments, at least one strand contains a 3' overhang of at least two nucleotides.

[0101] In some embodiments, the nucleotide modification on the sense and antisense strands is a 2' modification of the nucleotide ribose.

[0102] In some embodiments, the modification at the 2' position of the nucleotide ribose is selected from any one or a combination of several of the following: 2'-methoxy modification, 2'-methoxyethyl modification, 2'-fluoro modification, 2'-benzyloxy modification, 2'-methylcarbonylamino modification, and 2'-pyridinemethoxy modification.

[0103] In some embodiments, the modification at the 2' position of each nucleotide ribose is a combination of 2'-methoxy modification and 2'-fluoro modification.

[0104] In some embodiments, the modification at the 2' position of each nucleotide ribose is an alternating combination of 2'-methoxy modification and 2'-fluoro modification.

[0105] In some embodiments, the modification at the 2' position of each nucleotide ribose is as follows: the odd-numbered positions of the sense strand are all 2'-fluoro modified, and the even-numbered positions are all 2'-methoxy modified; and the odd-numbered positions of the antisense strand are all 2'-methoxy modified, and the even-numbered positions are all 2'-fluoro modified.

[0106] In some embodiments, the nucleotides are linked to each other by 3',5'-phosphodiester bonds.

[0107] In some embodiments, the nucleotides are linked to each other by 3',5'-phosphothiodiester bonds.

[0108] In some embodiments, the siRNA duplex has alternating fluorine-oxygen modification or template modification.

[0109] In some embodiments, phosphorylation of the 5' carbon atom of the modified antisense 5'-terminal nucleotide glycoside includes, but is not limited to, the following 5'-phosphorylating groups: 5'-vinylphosphonate group (5'-E-VP); 5'-methylphosphonate group (5'-MP); 5'-C-methylphosphate group; 5'-thiophosphate group (5'-PS); 5'-phosphate group (5'-P), the structure of which is shown below: ; wherein, R is hydrogen, hydroxyl, amino, C1-4 alkyl, aromatic, C1-4 alkoxy, C1-4 alkylcarbonylamino or halogen; the base is selected from adenine, guanine, cytosine, thymine and uracil.

[0110] In some embodiments, the first and second nucleotides at the 3' and / or 5' ends of the sense and / or antisense strands of the siRNA modifier are connected by a 3',5'-phosphothioester bond; for example, in some embodiments, a chiral pure 3',5'-phosphothioester bond is formed. In some embodiments, one, two, or three 3',5'-phosphothioester bonds may be present between the first and fourth nucleotides at the 5' end of the sense and / or antisense strands, and one, two, or three 3',5'-phosphothioester bonds may be present between the first and fourth nucleotides at the 3' end of the antisense strand.

[0111] In some embodiments, the antisense strand is modified in any of the following ways: Specification 16 / 91 page 39 CN 121801914 A Specification 17 / 91 page 40 CN 121801914 A

[0112]

[0113] and / or, the sense strand is modified in one of the following ways:

[0114] Wherein, 2'-OMe represents 2'-methoxy; 2'-F represents 2'-fluoro; PS represents starting from the 5' end, where the nucleotide at this position is connected to the adjacent nucleotide on its right by a 3',5'-thiophosphate bond; EVP represents 5'-vinyl-(E)-phosphonate.

[0115] In some embodiments, the antisense chain is modified by modification method A, and the justice chain is modified by modification method a; the antisense chain is modified by modification method B, and the justice chain is modified by modification method a; the antisense chain is modified by modification method C, and the justice chain is modified by modification method a; the antisense chain is modified by modification method C, and the justice chain is modified by modification method b; the antisense chain is modified by modification method D, and the justice chain is modified by modification method b; the antisense chain is modified by modification method E, and the justice chain is modified by modification method b; the antisense chain is modified by modification method F, and the justice chain is modified by modification method b; the antisense chain is modified by modification method G, and the justice chain is modified by modification method b; or the antisense chain is modified by modification method H, and the justice chain is modified by modification method b.

[0116] In some embodiments, the antisense strand is modified in any of the following ways: Specification 18 / 91 page 41 CN 121801914 A Specification 19 / 91 page 42 CN 121801914 A

[0117]

[0118] and / or, the sense strand is modified in one of the following ways:

[0119] Wherein, 2'-OMe represents 2'-methoxy; 2'-F represents 2'-fluoro; PS represents a nucleotide starting from the 5' end, where the nucleotide at this position is connected to its adjacent nucleotide on the right by a 3',5'-thiophosphate bond; EVP represents 5'-vinyl-(E)-phosphonate.

[0120] In some implementations, the antisense chain is modified by modification method A', and the justice chain is modified by modification method a'; the antisense chain is modified by modification method B', and the justice chain is modified by modification method a'; the antisense chain is modified by modification method C', and the justice chain is modified by modification method a'; the antisense chain is modified by modification method C', and the justice chain is modified by modification method b'; the antisense chain is modified by modification method D', and the justice chain is modified by modification method b'; the antisense chain is modified by modification method E', and the justice chain is modified by modification method b'; the antisense chain is modified by modification method F', and the justice chain is modified by modification method b'; the antisense chain is modified by modification method G', and the justice chain is modified by modification method b'; or the antisense chain is modified by modification method H', and the justice chain is modified by modification method b'.

[0121] In some embodiments, the siRNA duplex is selected from any one or a combination of at least two of the following: Specification 20 / 91 page 43 CN 121801914 A Specification 21 / 91 page 44 CN 121801914 A

[0122] Specification 22 / 91 page 45 CN 121801914 A

[0123] Specification 23 / 91 page 46 CN 121801914 A

[0124] Specification 24 / 91 page 47 CN 121801914 A

[0125] Specification 25 / 91 page 48 CN 121801914 A

[0126]

[0127] In some embodiments, the siRNA duplex comprises any one or a combination of at least two of the oligonucleotide duplexes composed of sense and antisense strands selected from those shown in Tables 5 and 12.

[0128] In some embodiments, the antisense strand and / or the sense strand employs a modifying group at any position from the second to the eleventh position from the 5' end, or at least two positions, wherein the modifying group is selected from UNA, GNA, or DNA, wherein the structures of UNA and GNA are as follows: ; wherein the bases are selected from adenine, guanine, cytosine, thymine, and uracil.

[0129] In some preferred embodiments, the 7th position, or the 7th and 11th positions of the antisense strand, are replaced with DNA, and the nucleotides at the complementary pairing positions of the sense strand and the 7th position of the antisense strand are also replaced with DNA.

[0130] This disclosure provides siRNA duplexes selected from any oligonucleotide duplexes formed by the sense and antisense strand pairings shown in Table 5, or at least a combination of both.

[0131] In some preferred embodiments, the siRNA duplex contains a sense and antisense strand pairing selected from the following:For any one or at least a combination of two of the constituent oligonucleotide duplexes: the positive strand has the sequence shown in SEQ ID NO: 261 or a modified sequence thereof; and the antisense strand has the sequence shown in SEQ ID NO: 391 or a modified sequence thereof; the positive strand has the sequence shown in SEQ ID NO: 262 or a modified sequence thereof; and the antisense strand has the sequence shown in SEQ ID NO: 392 or a modified sequence thereof; the positive strand has the sequence shown in SEQ ID NO: 263 or a modified sequence thereof; and the antisense strand has the sequence shown in SEQ ID NO: 393 or a modified sequence thereof; the positive strand has the sequence shown in SEQ ID NO: 264 or a modified sequence thereof; and the antisense strand has the sequence shown in SEQ ID NO: 394 or a modified sequence thereof; Specification 26 / 91 page 49 CN 121801914 A The positive strand has the sequence shown in SEQ ID NO: The sequence shown in SEQ ID NO: 265 or a modified sequence thereof; and the antisense chain having the sequence shown in SEQ ID NO: 395 or a modified sequence thereof; the positive chain having the sequence shown in SEQ ID NO: 266 or a modified sequence thereof; and the antisense chain having the sequence shown in SEQ ID NO: 396 or a modified sequence thereof; the positive chain having the sequence shown in SEQ ID NO: 267 or a modified sequence thereof; and the antisense chain having the sequence shown in SEQ ID NO: 397 or a modified sequence thereof; the positive chain having the sequence shown in SEQ ID NO: 268 or a modified sequence thereof; and the antisense chain having the sequence shown in SEQ ID NO: 398 or a modified sequence thereof; the positive chain having the sequence shown in SEQ ID NO: 269 or a modified sequence thereof; and the antisense chain having the sequence shown in SEQ ID NO: 399 or a modified sequence thereof; the positive chain having the sequence shown in SEQ ID NO: 269 or a modified sequence thereof; the positive chain having the sequence shown in SEQ ID NO: 269 or a modified sequence thereof; The sequence shown in SEQ ID NO: 270 or a modified sequence thereof; and the antisense chain having the sequence shown in SEQ ID NO: 400 or a modified sequence thereof; the positive chain having the sequence shown in SEQ ID NO: 271 or a modified sequence thereof; and the antisense chain having the sequence shown in SEQ ID NO: 401 or a modified sequence thereof; the positive chain having the sequence shown in SEQ ID NO: 272 or a modified sequence thereof; and the antisense chain having the sequence shown in SEQ ID NO: 272 or a modified sequence thereof;The sequence shown in 401 or a modified sequence thereof.

[0132] This disclosure also provides siRNA duplexes selected from any oligonucleotide duplexes formed by pairing sense and antisense strands as shown in Table 12, or a combination of at least both.

[0133] This disclosure provides an siRNA conjugate comprising the siRNA duplex as described herein and a conjugation group attached to the siRNA duplex.

[0134] The double-stranded ribonucleic acid and double-stranded ribonucleic acid modifiers of this disclosure may optionally be attached to one or more conjugation groups. The conjugation group may be attached to the sense strand, antisense strand, or both strands at the 3' end, 5' end, or both ends. For example, the conjugation group is attached at the 3' end or 5' end of the sense strand. In a preferred embodiment, the conjugation group is attached at the 3' end of the sense strand. In one embodiment, the conjugation group has any GalNAc structure.

[0135] In some embodiments, the conjugation group is one or more GalNAc derivatives attached using a divalent or trivalent branched linker arm.

[0136] Typically, the conjugation group comprises at least one pharmaceutically acceptable target group, or further comprises a linker, and the siRNA, the linker, and the target group are sequentially linked. In some embodiments, there are 1 to 6 target groups. In some embodiments, there are 2 to 4 target groups. In some embodiments, there are 3 target groups. The conjugation group may be covalently or non-covalently linked to the siRNA molecule, and the linking site may be at the 3' or 5' end of the siRNA's sense strand, at the 5' end of the antisense strand, or within the siRNA's internal sequence. In some embodiments, the linking site is at the 3' end of the siRNA's sense strand.

[0137] In some embodiments, the pharmaceutically acceptable target group may be a conventional ligand in the field of siRNA delivery, such as the various ligands described in WO2009082607A2, which are incorporated herein by reference in their entirety.

[0138] In some embodiments, each ligand is independently selected from a ligand capable of binding to a cell surface receptor. In some embodiments, at least one ligand is a ligand capable of binding to a hepatocyte surface receptor. In some embodiments, at least one ligand is a ligand capable of binding to a mammalian cell surface receptor. In some embodiments, at least one ligand is a ligand capable of binding to a human hepatocyte surface receptor. In some embodiments, at least one ligand is a ligand capable of binding to the liver surface desialylate glycoprotein receptor (ASGPR). The types of these ligands are described in detail by those skilled in the art. 27 / 91 pages 50 CN 121801914 AIt is known that its function is generally to bind to specific receptors on the surface of target cells, mediating the delivery of ligate-linked siRNA to target cells.

[0139] In some embodiments, the pharmaceutically acceptable targeting group in the siRNA conjugate can be galactose or N-acetylgalactosamine, wherein the galactose or N-acetylgalactosamine molecule can be monovalent, divalent, trivalent, or tetravalent. That is, after the siRNA molecule forms an siRNA conjugate with a conjugate group containing a galactose or N-acetylgalactosamine molecule as a targeting group, the molar ratio of the siRNA molecule to the galactose or N-acetylgalactosamine molecule in the siRNA conjugate is 1:1, 1:2, 1:3, or 1:4. In some embodiments, when the siRNA is linked to a conjugate group containing N-acetylgalactosamine, the N-acetylgalactosamine molecule is trivalent.

[0140] The targeting group can be linked to the siRNA molecule via a suitable adapter, and those skilled in the art can select a suitable adapter according to the specific type of the targeting group. For details on the types of connectors, targeting groups, and their connection methods with siRNA, please refer to the disclosure of WO2015006740A2, which is incorporated herein by reference in its entirety.

[0141] In some embodiments, the structural formula of the conjugating group is, for example: , where X is a hydroxyl protecting group or H, the hydroxyl protecting group being selected from acetyl, benzoyl, or isobutyryl; Y is an amine protecting group or H, the amine protecting group being selected from formyl, acetyl, propionyl, n-butyryl, or isobutyryl; n is an integer from 0 to 20; q, r, and s are each independently an integer from 1 to 7.

[0142] In some embodiments, the structure of the conjugating group is, for example: .

[0143] In some embodiments, the conjugating group is, for example: Specification 28 / 91 pages 51 CN 121801914 A

[0144] Wherein, X is oxygen, -N(Y)- or sulfur; Y is C1-4 alkyl or C6-10 aryl; R1 is oxygen or sulfur; R2 is hydrogen, -NH2, C1-4 alkyl, C6-10 aryl, C1-4 alkoxy or halogen; A is -(CH2)a-, -(CH2CH2O)b-, -((CH2)cNHCO)d- or -((CH2)cCONH)d-, where a is an integer from 1 to 15, b is an integer from 1 to 7, c is an integer from 1 to 7, and d is an integer from 1 to 5; B is -(CH2)e-, where e is an integer from 0 to 7; L is -CONH- or -NHCO-; X1 is -(CH2)f- or -(CH2CH2O)fCH2-, where f is an integer from 1 to 5; X2 is -(CH2)g-, where g is an integer from 1 to 6; X3 is oxygen or sulfur; Y1 is 0 or 1; Y2 is 0, 1, or 2; When Y3 is 1, X4 is CH2; when Y3 is 2, X4 is CH; when Y3 is 3, X3 is carbon; m is an integer from 0 to 4.n is an integer from 0 to 4.

[0145] In some embodiments, the conjugating group has, for example, any of the following structures: , , , Specification 29 / 91 page 52 CN 121801914 A, or.

[0146] In some embodiments, the siRNA conjugate of this disclosure may have any of the following structures: , , , Specification 30 / 91 page 53 CN 121801914 A, or.

[0147] In some embodiments, the conjugated group has, for example, the following structure:

[0148] wherein X is oxygen, -N(Y)- or sulfur; Y is C1-4 alkyl or C6-10 aryl; R1 is oxygen or sulfur; R2 is hydrogen, -NH2, C1-4 alkyl, C6-10 aryl, C1-4 alkoxy or halogen; A is -(CH2)a-, -(CH2CH2O)b-, -((CH2)cNHCO)d- or -((CH2)cCONH)d-, wherein a is an integer from 1 to 15, b is an integer from 1 to 7, c is an integer from 1 to 7, and d is an integer from 1 to 5; B is -(CH2)e-, wherein e is an integer from 0 to 7; L is -CONH- or -NHCO-; X1 is -(CH2)f- or -(CH2CH2O)fCH2-, f is an integer from 1 to 5; X2 is -(CH2)g-, where g is an integer from 1 to 6; X3 is oxygen or sulfur; Y1 is 0 or 1; Y2 is 0, 1, or 2; when Y3 is 1, X4 is CH2; when Y3 is 2, X4 is CH; when Y3 is 3, X3 is carbon; m is an integer from 0 to 4; n is an integer from 0 to 4; q is an integer from 0 to 4.

[0149] In some embodiments, the conjugating group has, for example, any of the following structures: (Page 54, CN 121801914 A, Page 31 / 91, CN 121801914 A, Page 55, CN 121801914 A, or...) Specification 33 / 91 pages 56 CN 121801914 A

[0150] In some embodiments, the siRNA conjugate of this disclosure has, for example, any of the following structures: , , , Specification 34 / 91 pages 57 CN 121801914 A, or.

[0151] In some embodiments, either or both of the sense strand and antisense strand of the siRNA duplex may be linked to conjugation groups G4, G5, G6, G7, G101, G102, G103, G105, or G106.

[0152] In some embodiments, either or both of the sense strand and antisense strand are linked to conjugation group G5.

[0153] In some embodiments, the conjugation group is linked to the 3' end of the sense strand.

[0154] In some embodiments, the siRNA conjugate comprises any one or a combination of at least two of any oligonucleotide duplexes formed by the positive and negative strand pairings shown in Tables 5, 12, and 16.

[0155] In some preferred embodiments, the siRNA conjugate comprises any one or a combination of at least two of any siRNA conjugates formed by the positive and negative strand pairings shown in Table 16.

[0156] This disclosure also provides a nucleic acid protein complex comprising the double-stranded region or the antisense strand of the aforementioned siRNA duplex or siRNA conjugate, and a nuclease.

[0157] In this disclosure, the term "nucleic acid protein complex" refers to the siRNA binding to the Argonaute protein (AGO) to form an RNA-induced silencing complex (RISC). The siRNA is then unstranded into a positive and negative strand. The positive strand is degraded, and the antisense strand (guide strand) RISC binds to a target mRNA homologous to the siRNA via base pairing. RISC has the function of a nuclease. siRNA guides RISC to cleave homologous single-stranded mRNA, causing the mRNA to lose its function, that is, it cannot be translated to produce protein, which is to "silence" the gene.

[0158] This disclosure also provides a recombinant vector comprising a nucleic acid component encoding a double-stranded siRNA as disclosed in this disclosure.

[0159] In some embodiments, the vector backbone of the recombinant vector is selected from recombinant viroid-derived circular RNA vectors, tRNA, rRNA scaffolds, and chimeric tRNA / pre-miRNA vectors.

[0160] This disclosure also provides a recombinant cell comprising the aforementioned double-stranded siRNA or recombinant vector.

[0161] In some embodiments, the recombinant cell is selected from *Pseudomonas thiophilus* and *Corynebacterium glutamicum* deficient in ribonuclease III.

[0162] As used herein, a "recombinant vector" is preferably a vector comprising a regulatory sequence operatively linked to a nucleotide sequence encoding the positive strand contained in the nucleic acid molecule of this disclosure. "Recombinant cell" is a cell in which at least one recombinant vector capable of expressing a nucleic acid molecule or at least one strand of such nucleic acid molecule has been introduced.

[0163] This disclosure also provides a method for preparing the siRNA described herein, the method comprising culturing the aforementioned recombinant cells and / or obtaining the siRNA by means of chemical synthesis.

[0164] This disclosure also provides a pharmaceutical composition comprising a double-stranded siRNA or siRNA conjugate of the present disclosure, and a pharmaceutically acceptable vector.

[0165] In one embodiment, a pharmaceutical composition comprising the iRNA as described herein and a pharmaceutically acceptable vector is provided herein.Pharmaceutical compositions. Pharmaceutical compositions containing siRNA duplexes or siRNA conjugates can be used to treat diseases or conditions associated with the expression or activity of the INHBE gene, such as metabolic disorders. Such pharmaceutical compositions are formulated based on delivery models. One example is a composition formulated for systemic administration via parenteral delivery, such as subcutaneous injection (SC).

[0166] Pharmaceutical compositions containing siRNA duplexes or siRNA conjugates of this disclosure can be, for example, solutions with or without a buffer or compositions containing a pharmaceutically acceptable carrier. Such compositions include, for example, aqueous or crystalline compositions, liposome formulations, micelle formulations, emulsions, and gene therapy carriers.

[0167] In the methods of this disclosure, the siRNA duplexes or siRNA conjugates can be administered in a solution. A free siRNA can be administered in a non-buffered solution, such as in physiological saline or in water. Alternatively, the free siRNA can also be administered in a suitable buffered solution. The buffered solution may include acetate, citrate, alcohol-soluble gluten, carbonate, or phosphate, or any combination thereof. In a preferred embodiment, the buffer solution is phosphate-buffered saline (PBS). The pH and volumetric molar osmotic concentration of the buffer containing the iRNA agent can be adjusted to make it suitable for administration to a subject.

[0168] In some embodiments, the buffer solution further comprises a reagent for controlling the molar osmotic concentration of the solution so that the molar osmotic concentration is maintained at a desired value, such as the physiological value in human plasma. Solutes that can be added to the buffer solution to control the molar osmotic concentration include (but are not limited to) proteins, peptides, amino acids, non-metabolitic polymers, vitamins, ions, sugars, metabolites, organic acids, lipids, or salts. In some embodiments, the reagent for controlling the molar osmotic concentration of the solution is a salt. In some embodiments, the reagent for controlling the molar osmotic concentration of the solution is sodium chloride or potassium chloride.

[0169] The pharmaceutical composition of this disclosure can be administered at a dose sufficient to inhibit the expression of the INHBE gene. Typically, the suitable dosage of the siRNA disclosed herein is in the range of about 0.001 to about 200.0 mg per kilogram of body weight per day, usually in the range of about 1 to 50 mg per kilogram of body weight per day. For example, RNAi agents (e.g., siRNA duplexes) can be administered in single doses of about 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7,3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, Instruction Manual 36 / 91 pages 59 CN 121801914 A 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, 20, 20.5, 21, 21.5, 22, 22.5, 23, 23.5, 24, 24.5, 25, 25.5, 26, 26.5, 27, 27.5 Administer at doses of 28, 28.5, 29, 29.5, 30, 31, 32, 33, 34, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 mg / kg.

[0170] The pharmaceutical composition can be administered once daily, or multiple times at different time intervals from 1 to 365 days, or the siRNA can be administered two, three, or more sub-dose at appropriate intervals within a year, or even administered via continuous infusion or delivery using a controlled-release formulation. In this case, the amount of siRNA contained in each sub-dose must be correspondingly less to achieve the total daily dose. Dosage units can also be compounded for delivery over several days, for example using conventional sustained-release formulations that provide sustained siRNA release over a timeframe of several days. Sustained-release formulations are well known in the art and are particularly useful for delivering reagents at specific sites, thereby allowing their use with the reagents of this disclosure. In this embodiment, the dosage unit comprises a corresponding plurality of daily doses.

[0171] In other embodiments, a single dose of the pharmaceutical composition may be sustained for an extended period, such that subsequent doses are administered at intervals of no more than 3, 4, or 5 days or at intervals of no more than 1, 2, 3, or 4 weeks. In some embodiments of this disclosure, a single dose of the pharmaceutical composition of this disclosure is given once weekly. In other embodiments of this disclosure, a single dose of the pharmaceutical composition of this disclosure is given once every two months.

[0172] Those skilled in the art will understand that certain factors can influence the dosage and duration required to effectively treat a subject.The timing of these factors includes (but is not limited to) the severity of the disease or condition, previous treatment, the subject's overall health and / or age, and other existing diseases. Furthermore, treating a subject with a therapeutically effective dose of the composition may include a single treatment or a series of treatments. As described elsewhere herein, the effective dose and in vivo half-life of the various siRNAs covered by this disclosure can be estimated using conventional methods or based on in vivo testing using suitable animal models.

[0173] Depending on whether local or systemic treatment is desired and depending on the area to be treated, the pharmaceutical compositions of this disclosure can be administered in a variety of ways. Administration can be local (e.g., via a skin patch); pulmonary; for example, by inhalation or blowing of powder or aerosol, including via a nebulizer; intratracheal; intranasal; epidermal; and percutaneous, oral, or parenteral. Parenteral administration includes intravenous, intra-arterial, subcutaneous, intraperitoneal, or intramuscular injection or infusion; subdermal, for example, via an implanted device; or intracranial, such as intraparenchymal, intrasheathal, or intraventricular administration.

[0174] The siRNA used in the compositions and methods of this disclosure can be formulated for delivery, for example, in a membrane-bound ensemble of molecules, such as liposomes or micelles. As used herein, the term "liposome" refers to a vesicle composed of amphiphilic lipids disposed in at least one lipid bilayer (e.g., one or more lipid bilayers), having an outer membrane formed of a lipophilic material and an aqueous portion located within it. This lipophilic material separates the aqueous interior from the aqueous exterior, which typically does not include the siRNA composition (although in some instances it may include it). Liposomes are useful for the transfer and delivery of active ingredients to sites of action. Because the liposome membrane is structurally similar to a biological membrane, when a liposome is applied to a tissue, the liposome bilayer fuses with the cell membrane bilayer. As the liposome fuses with the cell, the aqueous contents, including the siRNA, are delivered into the cell, where the siRNA can specifically bind to a target RNA and can mediate RNA interference (RNAi). In some cases, these liposomes are also specifically targeted, for example, to direct the siRNA to a specific cell type.

[0175] Liposomes containing RNAi agents can be prepared by a variety of methods. In one example, the lipid component of the liposome is dissolved in a detergent such that micelles are formed with the lipid component. For example, the lipid component can be an amphiphilic cationic lipid or a lipid conjugate. The detergent can have a high critical micelle concentration and can be nonionic. Exemplary detergents include cholates, CHAPS, octyl glucoside, deoxycholate, and lauroyl sarcosine. The RNAi agent formulation is then added to a mixture containing...The lipid component is contained in micelles. The cationic groups on the lipid interact with the RNAi agent and condense around the RNAi agent to form liposomes. After condensation, the detergent is removed, for example by dialysis, to obtain a liposomal formulation of the RNAi agent.

[0176] The RNAi agent, such as the siRNA duplex of this disclosure, can be completely encapsulated in a lipid formulation (e.g., LNP or other nucleic acid-lipid particles).

[0177] As used herein, the term "LNP" refers to a stable nucleic acid-lipid particle. An LNP contains a cationic lipid, a non-cationic lipid, and a lipid that prevents the particle from accumulating (e.g., a PEG-lipid conjugate). LNPs are extremely useful for synthetic applications because they exhibit prolonged cycle life after intravenous (iv) injection and accumulate at distal sites (e.g., at sites physically separate from the administration site).

[0178] In one embodiment, the mass ratio of lipid to drug is about 1:1 to about 50:1, about 1:1 to about 25:1, about 3:1 to about 15:1, about 4:1 to about 10:1, about 5:1 to about 9:1, or about 6:1 to about 9:1.

[0179] In some preferred embodiments, the lipid nanoparticles comprise cationic lipids, neutral lipids, structural lipids, and polymer-conjugated lipids.

[0180] In some preferred embodiments, the cationic lipid is a compound of formula (I), or its N-oxide, solvate, pharmaceutically acceptable salt, or stereoisomer, wherein G1 is a C1-6 alkylene; G2 is a C2-8 alkylene; G3 is a C1-3 alkylene; L1 is a C6-15 straight-chain alkyl; and L2 is a C12-25 branched-chain alkyl. For example, YK-009 of formula (I-I) (see patent CN114044741B).

[0181] (I) (I-I).

[0182] In some preferred embodiments, the cationic lipid is a compound of formula (II), or its N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer, wherein: G1 is a C2-8 alkylene; G2 is a C2-8 alkylene; L1 is -C(O)O- or -OC(O)-; L2 is -C(O)O- or -OC(O)-; R1 is a C6-25 straight-chain or branched alkyl; R2 is a C6-25 straight-chain or branched alkyl; G3 is HO(CH2)2- or HO(CH2)3-; G4 is HO(CH2)2- or HO(CH2)3-; L is (CH2)2- or -(CH2)3- or -(CH2)4-. For example, YK-401 with structure (II-I), YK-402 with structure (II-II), and YK-407 with structure (II-III), etc. (see patent CN115784921B, the entire contents of which are incorporated herein by reference, including, in particular, its...)(General formulas and specific compounds, etc.). Specification 38 / 91 pages 61 CN 121801914 A

[0183] (II) (II-I) (II-II) (II-III).

[0184] In some preferred embodiments, the cationic lipid is a compound of formula (III), or its N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer, wherein: G1 is a C1-6 alkylene; G2 is a C2-8 alkylene; R1 is a C6-20 straight-chain or branched alkyl; R2 is a C12-25 branched alkyl; G3 is: HO(CH2)2N(CH3)(CH2)2−, HO(CH2)2N(CH2CH3)(CH2)2−, (HO(CH2)2)2N(CH2)2−, CH3O(CH2)2N(CH3)(CH2)2−, (CH3)2N(CH2)3SC(O)O(CH2)2−, (CH3)2N(CH2)3SC(O)−, CH3NH(CH2)2N(CH3)(CH2)2− or CH3CH2NH(CH2)2−. For example, YK-201 with formula (III-I) and YK-202 with formula (III-II) (see patent CN115677518B, the entire contents of which are incorporated herein by reference, including, in particular, the general formula and specific compounds therein). Specification 39 / 91 pages 62 CN 121801914 A

[0185] (III) (III-I) (III-II).

[0186] In some preferred embodiments, the cationic lipid is a compound of formula (IV), or its N-oxide, solvate, pharmaceutically acceptable salt, or stereoisomer, wherein G1 is a C1-8 alkylene; G2 is a C2-8 alkylene; R1 is a C6-25 straight-chain or branched alkyl; R2 is a C12-25 straight-chain or branched alkyl; and G3 is: HO(CH2)2N(R3)CH2CH(OH)CH2-, wherein R3 is -CH3 or -CH2CH3 or -CH2CH2OH. For example, YK-305 of formula (IV-I) and YK-310 of formula (IV-II) (see patent CN115745820B, the entire contents of which are incorporated herein by reference, including, in particular, the general formula and specific compounds therein).

[0187] (IV) Specification 40 / 91 pages 63 CN 121801914 A (IV-I) (IV-II).

[0188] In some preferred embodiments, the cationic lipid is a compound of formula (V), or its N-oxidized form.Compounds, solvates, pharmaceutically acceptable salts or stereoisomers, wherein G1 and G2 are each independently unsubstituted C6-C10 alkylene groups; G3 is an unsubstituted C1-C12 alkylene group; R1 and R2 are each independently C6-C24 alkyl or C6-C24 alkenyl groups; R3 is OR5, N, -C(=O)OR4, -OC(=O)R4 or -NR5C(=O)R4; R4 is a C1-C12 hydrocarbon group; and R5 is H or a C1-C6 hydrocarbon group; for example, ALC0315 of formula (V-I) (see patent CN108368028B, the entire contents of which are incorporated herein by reference, including, in particular, the general formula and specific compounds thereof); (V) (V-I).

[0189] In some preferred embodiments, the cationic lipid is a compound of formula (VI), or its N-oxide derivative, solvate, pharmaceutically acceptable salt, or stereoisomer, wherein R4 is selected from -(CH2)nQ and -(CH2)nCHQR; Q is selected from the group consisting of: -OR, -OH, -O(CH2)nN(R)2, -OC(O)R, -CX3, -CN, -N(R)C(O)R, -N(H)C(O)R, -N(R)S(O)2R, -N(H)S(O)2R, -N(R)C(O)N(R)2, -N(H)C(O)N(R)2, -N(H)C(O)N(R)2, -N(H)C(O)N(H)(R), -N(R)C(S) N(R)2, -N(H)C(S)N(R)2, -N(H)C(S)N(H)(R), -N(R)S(O)2R8 and heterocycles; n is 1, 2 or 3; for example, SM102 of formula (VI-I) (see patent application CN110520409A, the entire contents of which are incorporated herein by reference, including, in particular, the general formula and specific compounds therein).

[0190] (VI) (VI-I).

[0191] In some preferred embodiments, the cationic lipid is a compound of formula (VII), or its N-oxide, solvate, pharmaceutically acceptable salt or stereoisomer (see patent CN102625696B, DLIN-MC3-DMA, the entire contents of which are incorporated herein by reference, including, in particular, the general formula and specific compounds therein),

[0192] (VII) (DLIN-MC3-DMA).

[0193] In some more preferred embodiments, the cationic lipid is selected from any one or a combination of at least two of the group consisting of YK-009, YK-401, YK-305, ALC0315, SM102, and DLIN-MC3-DMA.

[0194] In some preferred embodiments, the molar ratio of the cationic lipid to the neutral lipid is 1:1 to 10:1.

[0195] In some preferred embodiments, the molar ratio of the cationic lipid to the structural lipid is 1:1 to 5:1.

[0196] In some preferred embodiments, the molar ratio of the cationic lipid, the neutral lipid, the structural lipid, and the polymer-conjugated lipid is (25~65):(5~25):(25~70):(0.5~5).

[0197] In some preferred embodiments, the molar ratio of the cationic lipid, the neutral lipid, the structural lipid, and the polymer-conjugated lipid is (25~65):(5~25):(25~45):(0.5~5).

[0198] In some more preferred embodiments, the molar ratio of the cationic lipid, the neutral lipid, the structural lipid, and the polymer-conjugated lipid is 50:10:38.5:1.5 or 49:10:39.5:1.5.

[0199] In some preferred embodiments, the neutral lipid is selected from any one or a combination of at least two of the group consisting of phosphatidylcholine, phosphatidylethanolamine, sphingomyelin, ceramide, sterols, and their derivatives. In some more preferred embodiments, the neutral lipid is selected from any or a combination of at least two of the following: 1,2-dilinoleoyl-sn-glycerol-3-phosphate choline (DLPC), 1,2-dimyristoyl-sn-glycerol-3-phosphate choline (DMPC), 1,2-dioleoyl-sn-glycerol-3-phosphate choline (DOPC), 1,2-dipalmitoyl-sn-glycerol-3-phosphate choline (DPPC), 1,2-distearate-sn-glycerol-3-phosphate choline (DSPC), 1,2-diundecanoyl-sn-glycerol-3-phosphate choline (DUPC), 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphate choline (POPC), 1,2-di-O-octadecenyl-sn-glycerol-3-phosphate choline (18:0 Diether PC, 1-oleoyl-2-cholesterolyl-sn-glycerol-3-phosphate choline (OChemsPC), 1-hexadecyl-sn-glycerol-3-phosphate choline (C16 Lyso PC), 1,2-dilinolenoyl-sn-glycerol-3-phosphate choline, 1,2-disarachidonicyl-sn-glycerol-3-phosphate choline, 1,2-bis(docohexanoyl-sn-glycerol-3-phosphate choline), 1,2-dioleoyl-sn-glycerol-3-phosphate ethanolamine (DOPE), 1,2-diphydanyl-sn-glycerol-3-phosphate ethanolamine (ME)16.0PE), 1,2-distearyl-sn-glycerol-3-phosphate ethanolamine, 1,2-dilinoleoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-dilinolenoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-diarachidonicoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-bis(docosahexaenooyl-sn-glycerol-3-phosphate ethanolamine, 1,2-dioleoyl-sn-glycerol-3-phosphate-rac-(1-glycerol) sodium salt (DOPG), dipalmitoylphosphatidylglycerol (DPPG), palmitoyloleoylphosphatidylethanolamine (POPE), distearyl-phosphatidyl-ethanolamine (DSPE), dipalmitoylphosphatidyl-3-phosphate Dimethyl ether ethanolamine (DPPE), dimyristoyl phosphate ethanolamine (DMPE), 1-stearoyl-2-oleoyl-stearoyl ethanolamine (SOPE), 1-stearoyl-2-oleoyl-phosphatidylcholine (SOPC), sphingomyelin, phosphatidylcholine, phosphatidyl ethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyl oleoyl phosphatidylcholine, lysophosphatidylcholine, lysophosphatidyl ethanolamine (LPE), and mixtures thereof.

[0201] In some more preferred embodiments, the neutral lipid is DOPE and / or DSPC.

[0202] In some preferred embodiments, the structural lipid is selected from any or at least a combination of the following: cholesterol, nonsterols, sitosterol, ergosterol, campesterol, stigmasterol, brassinosteroids, tomatine, ursolic acid, α-tocopherol, and corticosteroids.

[0203] In some more preferred embodiments, the structural lipid is cholesterol.

[0204] In some preferred embodiments, the polymer-conjugated lipid is selected from any or at least a combination of the following: PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, PEG-modified dialkylglycerol.

[0205] In some more preferred embodiments, the polymer-conjugated lipid is selected from any or at least a combination of the following: distearate phosphatidylethanolamine polyethylene glycol 2000 (DSPE-PEG2000), dimyristoylglycerol-3-methoxy polyethylene glycol 2000 (DMG-PEG2000), and methoxy polyethylene glycol bis(tetradecylacetamide) (ALC-0159).

[0206] Examples of pharmaceutical compositions disclosed herein include, but are not limited to, aqueous formulations, emulsion formulations, and liposome-containing formulations. These compositions can be derived from a variety of components, examples of which include, but are not limited to, preformed liquids, self-emulsifying solids, and self-emulsifying semi-solids. For example, preferred formulations are those targeting the liver when treating liver conditions such as liver cancer.

[0207] The pharmaceutical formulations disclosed herein (which can be conveniently present in unit dosage forms) can be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include steps such as combining the active ingredients with the pharmaceutical carrier or excipient. Generally, these formulations are prepared by the following steps: uniformly and finely combining the active ingredients with a liquid carrier or a finely dispersed solid carrier, or both, and, if necessary, shaping the product. Specification 43 / 91 pages 66 CN 121801914 A

[0208] The compositions of this disclosure can be formulated into any of a number of possible dosage forms, such as, but not limited to, tablets, capsules, gelatin capsules, liquid syrups, soft capsules, suppositories, and enemas. The compositions of this disclosure can also be formulated as suspensions in aqueous, non-aqueous, or mixed media. Aqueous suspensions may further contain substances that increase the viscosity of the suspension, such substances including, for example, sodium carboxymethyl cellulose, sorbitol, and / or dextran. The suspension may also contain a stabilizer.

[0209] Certain compositions of this disclosure also incorporate a carrier compound into the formulation. As used herein, "carrier compound" or "carrier" may refer to a nucleic acid or the like, which is inert (i.e., not biologically active in itself) but is considered a nucleic acid in vivo, for example by reducing the bioavailability of biologically active nucleic acids by degrading them or promoting their removal from circulation. Co-administration of nucleic acids and carrier compounds (generally an excess of the latter) can result in a significant reduction in the amount of nucleic acid recovered from the liver, kidneys, or other external circulation reservoirs, presumably due to competition for a common receptor between the carrier compound and the nucleic acid. For example, when co-administered with polyinosinic acid, dextran sulfate, polycytidine, or 4-acetamido-4'-isothiocyanate 2,2'-disulfonic acid, the recovery of partially thiophosphated dsRNA in liver tissue can be reduced (Miyao et al., DsRNA Research and Development, 1995, 5, 115-121; Takakura et al., DsRNA & Nucleic Acid Drug Development, 1996, 6, 177-183).

[0210] Compared with a carrier compound, a "drug carrier" or "excipient" is a pharmaceutically acceptable solvent, suspension, or other pharmaceutically inert medium for delivering one or more nucleic acids to an animal. The excipient may be liquid or solid, and when combined with nucleic acids and other components of a particular pharmaceutical composition, the excipient is administered with reference to the intended manner of administration.The choice of volume, consistency, etc. is made to provide the desired volume. Typical drug carriers include, but are not limited to, binders (e.g., pregelatinized corn starch, polyvinylpyrrolidone, or hydroxypropyl methylcellulose); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylate, or dicalcium phosphate); lubricants (e.g., magnesium stearate, talc, silica, colloidal silica, stearic acid, metal stearates, hydrogenated vegetable oils, corn starch, polyethylene glycol, sodium benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium starch hydroxyacetate, etc.); and wetting agents (e.g., sodium lauryl sulfate, etc.).

[0211] Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration, which do not react toxically with nucleic acids, may also be used to formulate the compositions of this disclosure. Suitable pharmaceutically acceptable carriers include, but are not limited to: water, salt solutions, alcohols, polyethylene glycol, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethyl cellulose, polyvinylpyrrolidone, etc.

[0212] Formulations for topical administration of nucleic acids may include sterile or non-sterile aqueous solutions, non-aqueous solutions, or nucleic acid solutions in liquid or solid oil matrices in common solvents such as alcohols. These solutions may also include buffers, diluents, and other suitable additives. Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration and not toxic to nucleic acids may be used.

[0213] Suitable pharmaceutically acceptable excipients include, but are not limited to: water, salt solutions, alcohols, polyethylene glycol, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethyl cellulose, polyvinylpyrrolidone, etc.

[0214] This disclosure also provides methods for treating and / or preventing diseases and / or conditions that can be regulated by downregulating INHBE gene expression. The diseases and / or conditions mentioned include, but are not limited to, type 2 diabetes, hyperlipidemia or dyslipidemia (high or altered circulating levels of low-density lipoprotein cholesterol (LDL-C), triglycerides, very low-density lipoprotein cholesterol (VLDL-C), apolipoprotein B or other lipid fractions), obesity (especially abdominal obesity), lipodystrophy (such as the inability to deposit fat locally in fat deposits (partial lipodystrophy) or the inability to deposit fat systemically (lipomatosis)), insulin resistance or higher or altered insulin levels during fasting or metabolic challenges, hepatic steatosis or fatty liver disease and its complications (such as, for example, cirrhosis, fibrosis or liver inflammation), non-alcoholic steatohepatitis, other types of liver inflammation, liver enzyme levels or liver damage, higher or altered or elevated other markers of inflammation or steatosis in the liver, higher and / or hypertension, higher or hyperglycemia or blood glucose, metabolic syndrome, coronary artery disease and others.Atherosclerotic symptoms, complications of each of the above-mentioned symptoms, any other disease associated with elevated INHBE levels, and other unidentified related conditions, pathologies, or syndromes.

[0215] The siRNA of this disclosure may be administered to a subject using any method of administration known in the art, including (but not limited to) subcutaneous, intravenous, intramuscular, intraocular, intrabronchial, intrapleural, intraperitoneal, intraarterial, lymphatic, cerebrospinal, and any combination thereof. In a preferred embodiment, these agents are administered subcutaneously.

[0216] In another embodiment, the siRNA is administered in combination with another therapeutic agent. The siRNA and the other therapeutic agent may be administered in combination in the same composition, for example, parenteral, or the other therapeutic agent may be administered as part of a separate composition or by another method described herein.

[0217] Examples of the other therapeutic agents include agents known for treating INHBE-related diseases or conditions. For example, additional therapeutic agents include: administering one or more siRNAs of this disclosure to a subject; administering a non-INHBE RNAi therapeutic agent to a subject; and inducing behavioral changes in the subject. In some embodiments, the non-INHBE RNAi therapeutic agent is selected from any or a combination of at least two of the following: insulin, glucagon-like peptide-1 agonists, sulfonylureas, seglitinide, biguanides, thiazolidinediones, α-glucosidase inhibitors, SGLT2 inhibitors, DPP-4 inhibitors, HMG-CoA reductase inhibitors, and statins.

[0218] In one embodiment, an iRNA agent is given to a patient, and subsequently, an additional therapeutic agent is given to the patient (or vice versa). In another embodiment, the iRNA agent and the additional therapeutic agent are given simultaneously.

[0219] In another aspect, this disclosure provides a kit comprising a cartridge A, which includes one or more of the aforementioned siRNA duplexes, siRNA conjugates, nucleic acid-protein complexes, or pharmaceutical compositions.

[0220] In some embodiments, the kit further includes a box B containing one or more of the following: (1) other drugs that reduce INHBE gene expression or a composition containing said drugs that reduce INHBE gene expression; (2) one or more of the group consisting of insulin, glucagon-like peptide-1 agonists, sulfonylureas, seglinide, biguanides, thiazolidinediones, α-glucosidase inhibitors, SGLT2 inhibitors, DPP-4 inhibitors, HMG-CoA reductase inhibitors, and statins.

[0221] The "other drugs that reduce INHBE gene expression or a composition containing said drugs that reduce INHBE gene expression" described herein"Pharmaceutical composition" refers to a medicament that does not contain the siRNA dual-linked peptide, siRNA conjugate, or pharmaceutical composition provided in this disclosure.

[0222] This disclosure also provides the use of the aforementioned siRNA dual-linked peptide, siRNA conjugate, recombinant vector, recombinant cell, or pharmaceutical composition in the preparation of medicaments for the prevention and / or treatment of INHBE gene expression-related diseases.

[0223] In some embodiments, the INHBE gene expression-related diseases are selected from the following disease types: type 2 diabetes, hyperlipidemia or dyslipidemia (high or altered circulating levels of low-density lipoprotein cholesterol (LDL-C), triglycerides, very low-density lipoprotein cholesterol (VLDL-C), apolipoprotein B, or other lipid fractions), obesity (especially abdominal obesity). Lipomalfurcation (such as the inability to deposit fat locally in fat deposits (partial lipomatosis) or the inability to deposit fat throughout the body (lipoatrophy)), insulin resistance or higher or altered insulin levels during fasting or metabolic challenges, hepatic steatosis or fatty liver disease and its complications (e.g., cirrhosis, fibrosis, or liver inflammation), non-alcoholic steatohepatitis, other types of liver inflammation, liver enzyme levels or liver injury, higher or elevated or altered other markers of inflammation or steatosis in the liver, higher and / or hypertension, higher or hyperglycemia or blood glucose, metabolic syndrome, coronary artery disease and other atherosclerotic conditions, and complications of each of the above conditions.

[0224] This disclosure also provides a method for reducing INHBE gene expression or inhibiting INHBE replication for non-preventive and / or therapeutic purposes, the method comprising administering one or more of the aforementioned siRNA, conjugates, pharmaceutical compositions, and kits to a sample.

[0225] The term "not for preventative and / or therapeutic purposes" as used herein refers to reducing INHBE gene expression or inhibiting INHBE replication for research purposes, such as in a laboratory setting.

[0226] This disclosure also provides siRNAs, conjugates, pharmaceutical compositions, and / or kits described herein for the prevention and / or treatment of INHBE gene expression-related diseases.

[0227] This disclosure also provides methods for treating and / or preventing diseases and conditions that can be regulated by downregulating INHBE gene expression. For example, treating metabolic conditions associated with body fat distribution, including but not limited to: type 2 diabetes, hyperlipidemia or dyslipidemia (high or altered circulating levels of low-density lipoprotein cholesterol (LDL-C), triglycerides, very low-density lipoprotein cholesterol (VLDL-C), apolipoprotein B, or other lipid fractions), obesity (partial abdominal obesity), lipodystrophy (such as the inability to deposit fat locally in fat deposits (partial lipodystrophy) or the inability to deposit fat systemically).Fat deposition (lipoatrophy)), insulin resistance or higher or altered insulin levels during fasting or metabolic challenges, hepatic steatosis or fatty liver disease and its complications (e.g., cirrhosis, fibrosis, or liver inflammation), non-alcoholic steatohepatitis, other types of liver inflammation, liver enzyme levels or liver injury, higher or elevated or altered other markers of inflammation or fat deposition in the liver, higher and / or hypertension, higher or hyperglycemia, metabolic syndrome, coronary artery disease and other atherosclerotic conditions, and complications of each of the above conditions.

[0228] In some embodiments, the method includes administering a therapeutic and / or preventatively effective amount of the siRNA, conjugate, and / or pharmaceutical composition described in this disclosure to a subject in need, or administering it to the subject in need using a kit as described in this disclosure.

[0229] The RNAi agents of this disclosure can be administered to a subject using any route of administration known in the art, including (but not limited to) subcutaneous, intravenous, intramuscular, intraocular, intrabronchial, intrapleural, intraperitoneal, intraarterial, lymphatic, cerebrospinal, and any combination thereof. In a preferred embodiment, these agents are administered subcutaneously.

[0230] In another embodiment, the siRNA is administered in combination with another therapeutic agent. The siRNA and the other therapeutic agent can be administered in combination in the same composition, for example, parenterally, or the other therapeutic agent can be administered as part of a separate composition or by another method described herein.

[0231] Examples of other therapeutic agents include those known for treating metabolic disorders or cardiovascular diseases, including but not limited to insulin, glucagon-like peptide-1 agonists (e.g., exenatide, liraglutide, duraglutide, semaglutide, and pramlintide), sulfonylureas (e.g., chlorpropamide, glipizide), stiglinide (e.g., repaglinide, nateglipizide), biguanides (e.g., metformin), thiazolidinediones (e.g., rosiglitazone, troglitazone), α-glucosidase inhibitors (e.g., acarbose and megglitazone), SGLT2 inhibitors (e.g., dapagliflozin), DPP-4 inhibitors (e.g., linagliptin), or HMG- CoA reductase inhibitors, such as statins, including atorvastatin (Lipotor), fluvastatin (Lescol), lovastatin (Mevacor), lovastatin extended-release (Altoprev), pitavastatin (Livalo), pravastatin (Pravachol), rosuvastatin (Crestor), and simvastatin (Zocor).

[0232] In one embodiment, the siRNA agent is given to the patient, and subsequently another therapeutic agent is given to the patient (or vice versa). In another embodiment, the siRNA agent and another therapeutic agent are given simultaneously.

[0233] The present disclosure is further illustrated below by way of examples, but is not intended to limit the scope of the examples. Experimental methods not specifically described in the following examples are performed according to conventional methods and conditions, or according to the product instructions on page 46 / 91 of CN 121801914 A.

[0234] Unless otherwise specified, all reagents and raw materials used in this disclosure are commercially available.

[0235] The nucleotide abbreviations used herein are as follows: A = Adenosine-3'-phosphate Am = 2'-methoxyadenosine-3'-phosphate Ams = 2'-methoxyadenosine-3'-thiophosphate Af = 2'-fluoroadenosine-3'-phosphate Afs = 2'-fluoroadenosine-3'-thiophosphate G = Guanosine-3'-phosphate Gm = 2'-methoxyguanosine-3'-phosphate Gms = 2'-methoxyguanosine-3'-thiophosphate Gf = 2'-fluoroguanosine-3'-phosphate Gfs = 2'-fluoroguanosine-3'-thiophosphate C = Cytidine-3'-phosphate Cm = 2'-methoxycytidine-3'-phosphate Cms = 2'-methoxycytidine-3'-thiophosphate Cf = 2'-fluorocytidine-3'-phosphate Cfs = 2'-fluorocytidine-3'-thiophosphate U = Urate-3'-phosphate Ester Um=2'-methoxyuridine-3'-phosphate Ums=2'-methoxyuridine-3'-thiophosphate Uf=2'-fluorouridine-3'-phosphate Ufs=2'-fluorouridine-3'-thiophosphate AmsEVP=5'-vinyl-(E)-phosphonate-2'-methoxyadenosine-3'-thiophosphate UmsEVP=5'-vinyl-(E)-phosphonate-2'-methoxyuridine-3'-thiophosphate Agna=adenosine-diol nucleic acid Cgna=cytidine-diol nucleic acid Ggna=guanosine-diol nucleic acid Tgna=thymidine-diol nucleic acid Ugna=uridine-diol nucleic acid Examples of the code rules for siRNA motifs (or motifs), siRNA modifiers, siRNA conjugates, etc. in this article are as follows: The siRNA motif is the unmodified siRNA.

[0236] Sequences with alternating 2'-methoxy (2'-OMe) and 2'-fluoro (2'-F) modifications are prefixed with "-AL" after the motif number. For example, alternating modifications are designated as si075-AL, si751-AL, etc.

[0237] For siRNA modifiers modified with the specified templates, including those using the templates DV25P~DV29P, DV32P~DV34P, DV41P~DV43P, DV25SP~DV43SP, etc., the corresponding designation rule is: the name of the corresponding template is added after the motif. For example, for the motif si751, after modification with the DV25P template, the following sequence is obtained:The code for the modifier is si751-DV25P. Specification 47 / 91 pages 70 CN 121801914 A

[0238] For example, siRNA conjugates, the name of the conjugate group such as "G103" or "G101" is added to the end of the code for the corresponding modifier. For example, the modifier si751-DV25P is linked to the conjugate group G101, and its corresponding code is si751-DV25PG101. Some conjugates, in addition to the modification of the template, may further have anti-off-target modification (e.g., d7B or d7B11). The code for such conjugates containing the template and the anti-off-target modification is to add the corresponding template name and the anti-off-target modification name in sequence after the code for the corresponding motif, and add the name of the conjugate group such as "G103" or "G101" to the end.

[0239] Examples of siRNA double-stranded (motif, modification, conjugate) designations in this disclosure

[0240] Examples

[0241] In the following examples, the experimental data for inter-group comparisons showed p-values ​​<0.05, indicating statistical significance.

[0242] Other objects, features, and advantages of this disclosure will become apparent from the following detailed description. However, it should be understood that the detailed description and specific embodiments (although representing specific implementations of this disclosure) are given for illustrative purposes only, as various changes and modifications made within the spirit and scope of this disclosure will become apparent to those skilled in the art upon reading this detailed description.

[0243] The experimental techniques and methods used in this embodiment are conventional techniques unless otherwise specified. For example, experimental methods in the following embodiments without specific conditions are generally performed under conventional conditions such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the manufacturer's recommendations. The materials, reagents, etc., used in the embodiments are commercially available unless otherwise specified.

[0244] Those skilled in the art will understand that in the various embodiments of this disclosure, when the test substance in the experiment is an siRNA conjugate, the experimental data and results, including but not limited to inhibition rate, IC50, and IC40, can reflect the inhibition rate, IC50, IC40, etc. of the corresponding siRNA modifier of the siRNA conjugate. This presents no obstacle to understanding for those skilled in the art.

[0245] Example 1: Inhibition of INHBE gene by siRNA motif

[0246] In this embodiment, siRNAs as shown in Table 1 were designed and synthesized based on the INHBE mRNA sequence (NM_031479.5).The motifs were transfected into Huh7 cells via lipid nanoparticles (LNPs), and the inhibitory effect of each siRNA motif on the INHBE gene was detected by qPCR. The siRNA motifs with better inhibitory effect were screened out.

[0247] 1. Experimental materials

[0248] Test samples: siRNA motifs in Table 1.

[0249] Cell type: Huh7 liver cancer cell line (Guangzhou Darui Biotechnology, DR-Cell-01).

[0250] Drug solvent: sterile enzyme-free water, gibco Opti-MEM.

[0251] 2. Synthesis of siRNA motifs

[0252] Instruments and reagents: Qingke 192 P model DNA / RNA automatic synthesizer, whose solid phase carrier is a universal carrier of cross-linked polystyrene beads, model Primer support 5G Unylinker 350 (Cytiva manufacturer).

[0253] Preparation method: According to the monomer concentration of 0.15 M, the following nucleotide monomer solutions were prepared with acetonitrile: DMT-A-2'-O-TBDMS phosphorus amide monomer (Formula 1), DMT-C-2'-O-TBDMS phosphorus amide monomer (Formula 2), DMT-G-2'-O-TBDMS phosphorus amide monomer (Formula 3) and DMT-U-2'-O-TBDMS phosphorus amide monomer (Formula 4).

[0254] Formula 1 Formula 2 Formula 3 Formula 4 Nucleoside monomers were linked one by one from the 3'-5' direction according to the nucleotide arrangement sequence by solid-phase phosphorus amide method. Each linkage of a nucleoside monomer includes four steps: deprotection, coupling, oxidation or sulfidation, and hydroxyl protection. Among them, when the two nucleotides are linked by phosphate ester, the linkage of the next nucleoside monomer includes four steps: deprotection, coupling, oxidation, and hydroxyl protection. When two nucleotides are linked by a thiophosphate, the process of linking the next nucleotide monomer involves four steps: deprotection, coupling, sulfidation, and hydroxyl protection.

[0255] The preparation is carried out using the following steps: A solid support is loaded into the designated position of the synthesizer, and the corresponding product is obtained after several synthesis cycles. The synthesis cycle includes (1) deprotection, (2) coupling, (3) oxidation / sulfidation, and (4) hydroxyl protection. The cycle process and the reagents used are described as follows: (1) Deprotection: 3% dichloroacetic acid toluene solution is used as the deprotection reagent to remove the DMT protecting group, and then acetonitrile is used for washing.

[0256] (2) Coupling:

[0257] 0.25 M 5-ethylthiotetrazole is used as the activator to couple the acetonitrile solution of each nucleotide monomer, and then acetonitrile is used for rinsing.

[0258] (3) Oxidation / sulfidation

[0259] Oxidation: Oxidation was carried out using a 0.05 M iodine pyridine / water (90 / 10) solution as an oxidant, followed by acetonitrile.Rinse.

[0260] Sulfurization: Use 3% pyridine solution of hydroflavin as sulfiding agent for sulfidation, and then rinse with acetonitrile.

[0261] (4) Hydroxyl protection

[0262] Use 10% tetrahydrofuran solution of acetic anhydride (CAP A) tetrahydrofuran / pyridine / N-methylimidazolium 74 / 10 / 16 (v / v / v) (CAP B) as hydroxyl protecting agent for hydroxyl protection, and then rinse with acetonitrile.

[0263] Repeat the above operation, and cycle the above steps according to the set nucleotide arrangement order to obtain the positive or negative strand product with a specific sequence arrangement.

[0264] (5) Use 3% dichloroacetic acid toluene solution as deprotecting agent to remove the DMT protecting group of the last nucleotide, and then wash with acetonitrile.

[0265] (6) Ammonolysis and purification

[0266] The solid support after reaction was transferred to a reactor, concentrated ammonia (25-28%, mass percentage) was added, and ammonolysis was maintained at 60℃ for 12 h. After the system was cooled to room temperature, the mixture was filtered, and the filter cake was washed with a mixture of purified water and ethanol. The filtrates were combined, passed through a chromatography column, concentrated, and lyophilized to obtain a 2'-O-TBDMS protected product.

[0267] (7) De-TBDMS

[0268] DMSO and triethylamine hydrofluoric acid were added to the obtained product, and the reaction was carried out at 60℃ for 2 h. Then, ammonium acetate aqueous solution was added to the reaction solution, shaken and mixed, anhydrous ethanol was added, and the mixture was shaken and mixed. Crystallization was carried out at -20℃ for 8-12 h. After centrifugation, the supernatant was discarded, and the precipitate was washed with anhydrous ethanol to obtain an unmodified single-chain product.

[0269] (8) Annealing

[0270] The sense and antisense strands of the obtained siRNA motif were mixed at a molar ratio of 1:1, heated to 95°C and held for 3 min, and then slowly cooled to room temperature to form a double strand of the siRNA motif.

[0271] The siRNAs in Table 1 were synthesized according to the above method.

[0272] Table 1: siRNA motif specification 50 / 91 pages 73 CN 121801914 A specification 51 / 91 pages 74 CN 121801914 A

[0273] specification 52 / 91 pages 75 CN 121801914 A

[0274]

[0275] 3. Experimental methods

[0276] The experimental method for the inhibitory effect of siRNA motif on the INHBE gene is the same as the method provided in other embodiments of the present invention, that is, the final siRNA concentration per well is 0.07 nM, the only difference being that the test sample is an siRNA motif.

[0277] 4. Experimental Results

[0278] The inhibition rate of INHBE mRNA expression by the basic sequence is shown in Table 2 below. (Instruction manual, page 53 / 91, 76)CN 121801914 A

[0279] Table 2

[0280] Example 2: Inhibition of INHBE gene by siRNA modified with DV29P template

[0281] 2.1 Design and synthesis of siRNA modified with DV29P template

[0282] To improve the inhibition efficiency and stability of the sequence, the siRNA motif in Example 1 was modified with DV29P or DV29SP templates (the modification types are shown in Tables 3 and 4 below). The sequences of siRNA modified with DV29P or DV29SP templates are shown in Table 5.

[0283] Table 3: Examples of DV29P modified templates

[0284] Table 4: Examples of DV29SP modified templates (Page 54 / 91, CN 121801914 A)

[0285] Table 5: Sequences of siRNA modified by DV29P or DV29SP modified templates (Page 55 / 91, CN 121801914 A) (Page 56 / 91, CN 121801914 A)

[0286] (Page 57 / 91, CN 121801914 A)

[0287] (Page 58 / 91, CN 121801914 A)

[0288] (Page 59 / 91, CN 121801914 A)

[0289] (Page 60 / 91, CN 121801914 A)

[0290] Instruction manual, pages 61 / 91, 84 CN 121801914 A

[0291]

[0292] Instruments and reagents: Qingke 192 P model DNA / RNA automatic synthesizer, its solid phase carrier is a universal carrier of cross-linked polystyrene beads, model Primer support 5G Unylinker 350 (Cytiva manufacturer).

[0293] Preparation method: The following nucleotide monomer solutions were prepared with acetonitrile at a monomer concentration of 0.15 M: DMT-A-OMe phosphoramidite monomer (Formula 5), ​​DMT-C-OMe phosphoramidite monomer (Formula 6), DMT-G-OMe phosphoramidite monomer (Formula 7), DMT-U-OMe phosphoramidite monomer (Formula 8), DMT-A-F phosphoramidite monomer (Formula 9), DMT-C-F phosphoramidite monomer (Formula 10), DMT-G-F phosphoramidite monomer (Formula 11), and DMT-U-F phosphoramidite monomer (Formula 12).

[0294] When synthesizing the 5' end base (the last base) of the antisense chain, a monomer containing a phosphonic acid group at the 5' end was used, for example...For example, vinyl-(E)-phosphonate-A-OMe phosphorous amide monomer (Formula 13), vinyl-(E)-phosphonate-U-OMe phosphorous amide monomer (Formula 14). Specification 62 / 91 pages 85 CN 121801914 A

[0295]

[0296] By solid-phase phosphorous amide method, nucleoside monomers are linked one by one in the 3'-5' direction according to the nucleotide arrangement sequence. Each linkage of a nucleoside monomer includes four steps: deprotection, coupling, oxidation or sulfidation, and hydroxyl protection. Among them, when two nucleotides are linked by phosphate ester, the linkage of the next nucleoside monomer includes four steps: deprotection, coupling, oxidation, and hydroxyl protection. When two nucleotides are linked by thiophosphate ester, the linkage of the next nucleoside monomer includes four steps: deprotection, coupling, sulfidation, and hydroxyl protection.

[0297] The preparation is carried out using the following steps: A solid support is loaded into the designated position of the synthesizer, and the corresponding product is obtained after several synthesis cycles. The synthesis cycle includes (1) deprotection, (2) coupling, (3) oxidation / sulfidation and (4) hydroxyl protection. The cycle process and the reagents used are described as follows on page 63 / 91 of the instruction manual, 86 CN 121801914 A: (1) Deprotection: 3% dichloroacetic acid toluene solution is used as the deprotection reagent to remove the DMT protecting group, and then acetonitrile is used for washing.

[0298] (2) Coupling:

[0299] 0.25M 5-ethylthiotetrazole is used as the activator to couple the acetonitrile solution of each nucleotide monomer, and then acetonitrile is used for washing.

[0300] (3) Oxidation / sulfidation:

[0301] Oxidation: 0.05M iodine in pyridine / water (90 / 10) solution is used as the oxidant for oxidation, and then acetonitrile is used for washing.

[0302] Sulfurization: Sulfurization was performed using a pyridine solution of 3% hydroflavin as the sulfiding agent, followed by rinsing with acetonitrile.

[0303] (4) Hydroxyl protection

[0304] Hydroxyl protection was performed using a 10% acetic anhydride tetrahydrofuran solution (CAP A) tetrahydrofuran / pyridine / N-methylimidazolium 74 / 10 / 16 (v / v / v) (CAP B) as the hydroxyl protecting agent, followed by rinsing with acetonitrile.

[0305] The above operation was repeated in a cycle according to the set nucleotide arrangement order to obtain the positive or negative strand product with a specific sequence arrangement.

[0306] (5) The DMT protecting group of the last nucleotide was removed using a 3% dichloroacetic acid toluene solution as the deprotecting agent, followed by washing with acetonitrile.

[0307] (6) Ammonolysis and purification

[0308] The solid support was transferred to the reactor, and concentrated ammonia (25-28%, mass percentage) was added. After ammonolysis was maintained at 60°C for 12 hours, the system was cooled to room temperature, and the mixture was transferred to a filter press. The filter cake was treated with a mixed solution of purified water and ethanol.Wash, combine the filtrates, pass through a chromatography column, concentrate, freeze dry, and obtain the product.

[0309] (7) Annealing

[0310] After mixing the purified sense and antisense strands in a 1:1 ratio, heat to 95℃ and hold for 3 min, then slowly cool to room temperature to form double strands.

[0311] 2.2 Inhibition of INHBE gene

[0312] The siRNA modified by the DV29P modified template synthesized in 2.1 was transfected into Huh7 cells through lipid nanoparticles (LNP), and the inhibitory effect on the INHBE gene was detected by qPCR.

[0313] (1) Experimental materials

[0314] Test sample: siRNA modified as listed in 2.1.

[0315] Cell type: Huh7 cell line

[0316] Drug solvent: sterile enzyme-free water, gibco Opti-MEM.

[0317] (2) Experimental methods

[0318] qRT-PCR was used to detect the inhibition of INHBE gene mRNA expression in the Huh7 cell line.

[0319] (2.1) Cell culture

[0320] The passaged Huh7 cell line was taken, and the logarithmically growing cells were cultured in 10% fetal bovine serum DMEM medium (supplemented with 100× penicillin and 100× streptomycin 10 μL / mL), and placed in a cell culture incubator containing 5% CO2 at 37℃, with the medium changed once a day. The cells were passaged with 0.25% trypsin, centrifuged at 800 r / min for 3 min, the supernatant was discarded, and fresh medium was added for passage culture. Instructions for Use, Pages 64 / 91, 87, CN 121801914 A

[0321] (2.2) Cell Transfection

[0322] Preparation of Transfection Mixture: Mix Lipofectamine RNAiMAX (Invitrogen, 13778150) and Opti-MEM at a volume ratio of 2:98 and vortex to mix.

[0323] siRNA Dilution: Dilute the siRNA sample to a suitable concentration using Opti-MEM to prepare the siRNA solution to be tested.

[0324] Preparation of Transfection Reagent: Add 65 μL of 0.84 nM or 0.36 nM siRNA solution diluted with Opti-MEM at a volume ratio of 1:1 to 65 μL of transfection mixture, vortex to mix, and let stand at room temperature for 15 min to obtain lipid nanoparticles (LNP). Take 12.5 μL for encapsulation efficiency detection.

[0325] Blank control group transfection reagent: Add 65 μL of the prepared transfection mixture to 65 μL of Opti-MEM. Vortex to mix and let stand at room temperature for 15 min.

[0326] Add 100 μL of the prepared transfection reagent with different siRNA concentrations to each well, along with 500 μL of cell suspension (containing 1.0 × 10⁵ cells per ml) pre-added to each well.In a 24-well cell culture plate containing 100 cells, the final siRNA concentration per well was 0.07 nM or 0.03 nM. 500 μL of cell suspension (1.0 × 10⁵ cells per mL) was added. After mixing with the cross-hatching method, the plate was placed in a 37°C, 5% CO₂ cell culture incubator and cultured for 40 h.

[0327] (2.3) INHBE mRNA detection

[0328] 1) RNA extraction

[0329] a. The culture medium in the 12-well plate was aspirated, and 0.5 mL of 1 × PBS was added to each well to wash the cells. The PBS was then aspirated. 0.5 mL of TRIzol reagent was added to the well, and the cells were thoroughly lysed by pipetting. The cells were then transferred to 1.5 mL of RNase-free EP tubes and incubated at room temperature for 5 min.

[0330] b. 0.1 mL of chloroform was added to each tube, and the tube was shaken vigorously for 15 sec and incubated at room temperature for 5 min. Centrifuge at 4℃, 12000 × g for 15 min, and transfer 200 μL of the supernatant to a new EP tube.

[0331] c. Add an equal volume of isopropanol, gently mix the liquid in the tube by inverting it, let it stand at -20℃ for 10 min, centrifuge at 4℃, 12000 × g for 15 min, and discard the supernatant.

[0332] d. Add 0.5 mL of 75% ethanol, gently wash the RNA precipitate, centrifuge at 4℃, 12000 × g for 5 min, and remove the supernatant. Repeat the rinsing once, centrifuge at 4℃, 12000 × g for 1 min, and remove the residual ethanol with a micropipette tip.

[0333] e. Air dry the residual ethanol at room temperature for 2–3 min, add 40 μL of RNase-free ddH2O, and dissolve.

[0334] 2) RNA concentration detection

[0335] The RNA concentration was detected using a nanodrop. Use 2 μL RNase-free ddH2O as a blank control, and use 2 μL RNA sample for detection each time. Record the sample concentration.

[0336] 3) INHBE mRNA reverse transcription

[0337] Mix reverse transcription reagent (Takara, RR092A), RNA solution and water at a volume ratio of 2:5:3, and react in a PCR instrument at 37 ℃ for 15 min, 85 ℃ for 5 s, and finally maintain at 4 ℃. Dilute the cDNA obtained after the reaction with sterile enzyme-free water 5 times.

[0338] 4) INHBE mRNA quantitative detection

[0339] In a 15 mL centrifuge tube, add qPCR reagent (Takara, RR420W), upstream primer and downstream primer at a volume ratio of 5:0.1:0.1 and mix well, and label it as solution A.

[0340] The primer sequence is as follows: hGAPDH-F: 5'-CTGGGCTACACTGAGCACC-3' (SEQ ID NO: 521)hGAPDH-R: 5'-AAGTGTCGTTGAGGGCAATG-3' (SEQ ID NO: 522) INHBE-F: 5'-TGTGTCCCTACTGCCCGAA-3' (SEQ ID NO: 523) Instruction manual 65 / 91 pages 88 CN 121801914 A INHBE-R: 5'-CCATATCTGGCACATCCGTCTT-3' (SEQ ID NO: 524) Label 1.5 mL EP tubes, add diluted cDNA and water at a volume ratio of 1:3.8 and mix well, label as solution B.

[0341] Add 5.2 μL of solution A + 4.8 μL of solution B to each well of a 96-well PCR plate. Cover with sealing film, centrifuge at 3000 rpm for 1 min, and perform detection.

[0342] This step is performed on ice to maintain low temperature conditions.

[0343] Place the plate in a qPCR instrument and run the following program: Pre-denaturation: 95℃, 30 sec; Cyclic reaction: 95℃, 5 sec; 60℃, 34 sec; 40 cycles; Melting curve: 95℃, 15 sec; 60℃, 60 sec; 95℃, 15 sec.

[0344] The running time is approximately 2 h. Analyze the experimental results and calculate 2 - ΔΔCt using the following formula: ΔCT = Average Ct value of the target gene INHBE - Average Ct value of the internal reference gene hGAPDH; ΔΔCT = ΔCT (detection sample group) - ΔCT (RNAiMAX control group); Relative expression level of target gene mRNA = 2 - ΔΔCt. The average Ct value is automatically calculated by Quant Studio 5 software under default settings; the RNAiMAX control group is the group without siRNA compared to the detection sample group.

[0345] (2.4) Calculation of inhibition rate

[0346] The formula for calculating the expression rate (%) of INHBE mRNA is: Expression rate = relative expression level of target gene INHBE mRNA × 100%; INHBE gene expression inhibition rate (%) = 100% - expression rate.

[0347] (3) Experimental results

[0348] The inhibition rate in this example is the average of three experiments. The inhibition rates of each sequence on the expression of INHBE mRNA in Huh7 cells are shown in Table 6.

[0349] The experimental results show that some sequences modified with template DV29P or DV29SP have different degrees of inhibitory effect on the expression of INHBE mRNA in Huh7 cells. Among them, the inhibition rates of si079-DV29SP, si791-DV29P, si075-DV29P and si751-DV29P exceed 60%.

[0350] Table 6 SpecificationPage 66 / 91, 89 CN 121801914 A

[0351] (4) siRNAs with similar sequences may also have large differences in activity.

[0352] Table 7: Comparison of the inhibition rate of INHBE by siRNA modified sequences with similar base sequences. Page 67 / 91, 90 CN 121801914 A

[0353] As can be seen from Table 7, some siRNAs with similar sequences have very different inhibitory effects on the expression of INHBE mRNA.

[0354] At a concentration of 0.03 nM: The sequence si028-DV29P is different from the sequence si029-DV29P only in the last two bases, but the inhibition rate of si029-DV29P is 63.4% higher than that of si029-DV29P.

[0355] The sequence si033-DV29SP differs from the sequence si034-DV29P only in the last two bases, but the inhibition rate of si033-DV29P is 30.0% higher than that of si034-DV29P.

[0356] The sequence si045-DV29P differs from the sequence si046-DV29P only in the last one base, but the inhibition rate of si045-DV29P is 30.9% lower than that of si046-DV29P.

[0357] Example 3: Inhibition of the INHBE gene by siRNA modified with a modified template

[0358] In this example, the motif in Example 1 was modified with multiple modified templates, including DV25P, DV26P, DV27P, DV29P, DV32P, DV34P, DV25SP, DV26SP, DV27SP, DV29SP, DV32SP, DV34SP, DV41P~DV43P or DV41SP~DV43SP, etc.

[0359] Natural 5' end phosphorylation or simple direct 5' end phosphorylation may result in dephosphorylation in the cell. Direct 5' end phosphorylation oligonucleotide chains can show 90% dephosphorylation after circulating in the blood for 2 hours and disappear completely after 24 hours. The 5' end phosphorylation design (5'-E-VP) uses E-vinylphosphonate to replace the bridging oxygen, which has improved phosphorylation effect and stability. The modified templates DV25P-DV27P, DV29P, DV32P, DV34P, DV41P-DV43P, DV25SP-DV27SP, DV29SP, DV32SP, DV34SP, and DV41SP-DV43SP all contain a 5'-vinylphosphonate group at the 5' end of the antisense chain.

[0360] 1. Experimental Materials

[0361] Test Samples: The sequences listed in Table 12 were obtained by using different templates (DV25P, DV26P, DV27P, DV32P, DV34P, DV41P, ...). (Instructions for Use)Page 68 / 91, CN 121801914 A DV42P, DV43P, DV22, DV25SP, DV26SP, DV27SP, DV32SP, DV34SP, DV41SP, DV42SP, DV43SP, DV22S) are obtained by modifying the basic sequences si075, si751, si753, si791, si014, si076, si077, si078, si080, si752, si079, si047, si754, si755, si756, si792, si141, si761, si771, si781 and si801 in Example 1.

[0362] Cell type: Huh7 cell line

[0363] Drug solvent: sterile enzyme-free water, gibco Opti-MEM

[0364] Sequence synthesis: siRNA sequence was synthesized according to the method in Example 1.

[0365] The modification rules of the template of this disclosure are as follows: (1) For compounds with 23 / 21 bases for the sense and antisense chains respectively, the antisense chain adopts any of the modification methods shown in Table 8 below: Table 8: Antisense chain modification instructions 69 / 91 pages 92 CN 121801914 A

[0366]

[0367] The sense chain adopts any of the modification methods shown in Table 9 below: Table 9: Sense chain modification

[0368] Wherein, 2'-OMe represents 2'-methoxy; 2'-F represents 2'-fluoro; PS represents starting from the 5' end, the nucleotide at this position is connected to the adjacent nucleotide on its right by a 3',5'-thiophosphate bond; EVP represents 5'-vinyl-(E)-phosphonate.

[0369] The siRNA modification template of the antisense strand using modification method A and the sense strand using modification method a is named DV25P.

[0370] The siRNA modification template of the antisense strand using modification method B and the sense strand using modification method a is named DV26P. Specification 70 / 91 pages 93 CN 121801914 A

[0371] The siRNA modification template of the antisense strand using modification method C and the sense strand using modification method a is named DV27P.

[0372] The siRNA modification template of the antisense strand using modification method C and the sense strand using modification method b is named DV29P.

[0373] The siRNA modification template of the antisense strand using modification method D and the sense strand using modification method b is named DV32P.

[0374] The siRNA modification template of the antisense strand using modification method E and the sense strand using modification method b is named DV34P.

[0375] The siRNA template modified with modification method F for the antisense strand and modification method b for the sense strand was named DV41P.

[0376] The siRNA modification template for the antisense strand using modification method G and the sense strand using modification method b is named DV42P.

[0377] The siRNA modification template for the antisense strand using modification method H and the sense strand using modification method b is named DV43P.

[0378] The siRNA modification template for the antisense strand using modification method I and the sense strand using modification method c is DV22.

[0379] (2) For compounds with 20 / 22 bases for the sense and antisense strands respectively, the antisense strand uses any of the modification methods shown in Table 10 below: Table 10: Antisense strand modification specification 71 / 91 pages 94 CN 121801914 A

[0380]

[0381] Wherein, 2'-OMe represents 2'-methoxy; 2'-F represents 2'-fluoro; PS represents starting from the 5' end, the nucleotide at this position is connected to the adjacent nucleotide on its right by a 3',5'-thiophosphate bond; EVP represents 5'-vinyl-(E)-phosphonate.

[0382] The sense strand adopts any of the modification methods shown in Table 11 below: Table 11: Sense strand modification

[0383] Wherein, 2'-OMe represents 2'-methoxy; 2'-F represents 2'-fluoro; PS represents starting from the 5' end, where the nucleotide at this position is connected to the adjacent nucleotide on its right by a 3',5'-thiophosphate bond; EVP represents 5'-vinyl-(E)-phosphonate.

[0384] The antisense strand adopts modification method A', and the siRNA modification template of the sense strand adopting modification method a' is named DV25SP; The antisense strand adopts modification method B', and the siRNA modification template of the sense strand adopting modification method a' is named DV26SP; The antisense strand adopts modification method C', and the siRNA modification template of the sense strand adopting modification method a' is named DV27SP; The antisense strand adopts modification method C', and the siRNA modification template of the sense strand adopting modification method b' is named DV29SP.

[0385] The siRNA modification template for the antisense strand using modification method D' and the sense strand using modification method b' is named DV32SP.

[0386] The siRNA modification template for the antisense strand using modification method E' and the sense strand using modification method b' is named DV34SP.

[0387] The siRNA modification template for the antisense strand using modification method F' and the sense strand using modification method b' is named DV41SP.

[0388] The siRNA modification template for the antisense strand using modification method G' and the sense strand using modification method b' is named DV42SP.

[0389] The siRNA modification template for the antisense strand using modification method H' and the sense strand using modification method b' is named DV43SP.

[0390] The siRNA modification template for the antisense strand using modification method I' and the sense strand using modification method c' is named DV22S.

[0391] The template-modified siRNAs are detailed in Table 12 below, and the synthesis methods for each sequence are described in the corresponding content above.

[0392] Table 12: Sequences of the sense and antisense strands of siRNA modifiers Specification 72 / 91 pages 95 CN 121801914 A Specification 73 / 91 pages 96 CN 121801914 A

[0393] Specification 74 / 91 pages 97 CN 121801914 A

[0394] Specification 75 / 91 pages 98 CN 121801914 A

[0395] Specification 76 / 91 pages 99 CN 121801914 A

[0396] Specification 77 / 91 pages 100 CN 121801914 A

[0397] Specification 78 / 91 pages 101 CN 121801914 A

[0398] Specification 79 / 91 pages 102 CN 121801914 A

[0399] Instructions for Use, Pages 80 / 91, 103, CN 121801914 A

[0400]

[0401] 2. Experimental Methods

[0402] The inhibition of INHBE gene mRNA expression in the Huh7 cell line by the test samples was detected by qRT-PCR.

[0403] 2.1 Cell Culture

[0404] The passaged Huh7 cell line was taken, and the logarithmically growing cells were cultured in 10% fetal bovine serum DMEM medium (supplemented with 100 μL / mL each of penicillin and streptomycin) and placed in a cell culture incubator containing 5% CO2 at 37℃. The medium was changed once a day. The cells were passaged with 0.25% trypsin, centrifuged at 1000 r / min for 5 min, the supernatant was discarded, and fresh medium was added for passage culture.

[0405] 2.2 Cell Transfection

[0406] Preparation of transfection mixture: Lipofectamine RNAiMAX and Opti-MEM were mixed at a ratio of 2:98 and vortexed to mix.

[0407] siRNA dilution: The siRNA sample was diluted to a suitable concentration using Opti-MEM to prepare the siRNA solution to be tested.

[0408] Transfection reagent preparation: 60 μL of Opti-MEM diluted siRNA solution was added to 60 μL of transfection mixture at a ratio of 1:1 (v / v). After vortexing and mixing, the mixture was allowed to stand at room temperature for 15 min to obtain lipid nanoparticles (LNP). 12.5 μL was used for encapsulation efficiency detection.

[0409] Blank control group transfection reagent: 60 μL of the prepared transfection mixture was added to 60 μL of Opti-MEM. After vortexing and mixing, the mixture was allowed to stand at room temperature for 15 min.

[0410] The prepared transfection reagents of different siRNA concentrations were added to each well at a ratio of 100 μL to 500 μL of pre-filled 400 μL of Opti-MEM.The siRNA concentration was increased to 0.02 nM or 0.07 nM per well by adding μL of cell suspension (1.0 × 10⁵ cells per milliliter) to a 24-well cell culture plate. After mixing using the cross-hatching method, the plate was placed in a 37°C, 5% CO₂ cell culture incubator and cultured for 40 h.

[0411] 2.3 INHBE mRNA detection

[0412] The steps were the same as in "(2.3) INHBE mRNA detection" in Example 2.

[0413] 2.4 Calculation of inhibition rate

[0414] The calculation method was the same as in Example 2. Instruction manual 81 / 91 pages 104 CN 121801914 A

[0415] 2.5 IC50 experiment

[0416] The siRNA modifiers used for IC50 assay were serially diluted, starting from 1.0 nM and 4-fold diluted, for a total of 8 concentration points (1.0 nM, 0.25 nM, 0.0625 nM, 15.6 pM, 3.9 pM, 0.977 pM, 0.244 pM and 0.061 pM), and the inhibition rate of each modifier at each concentration was measured, plotted, and IC50 was calculated.

[0417] 3. Experimental results

[0418] (1) After 3 repeated experiments, the inhibition rate of each modified sequence on the INHBE gene of Huh7 cells is shown in Table 13.

[0419] The results of the activity detection experiment showed that the modification with the modified templates DV25P–DV27P, DV29P, DV32P, DV34P, DV41P–DV43P, DV25SP–DV27SP, DV29SP, DV32SP, DV34SP, and DV41SP–DV43SP had a significant inhibitory effect on the INHBE gene, with an inhibition rate of over 40% at a concentration of 20 pM.

[0420] Table 13

[0421] (2) The same siRNA sequence showed certain activity differences after being modified with different modified templates.

[0422] Table 14: Inhibition rate of si079 sequence against INHBE mRNA using different modified templates (0.02 nM) Manual 82 / 91 pages 105 CN 121801914 A

[0423] As shown in Table 14, the same siRNA sequence showed certain activity differences after being modified with different modified templates. For example, the inhibitory rate of si079 modified with modified template DV25SP was 10.6% higher than that of the inhibitor modified with modified template DV41SP.

[0424] (3) IC50 experiment

[0425] Some template modification sequences were selected, including si751-DV25P, si791-DV26P, si047-DV34SP,Sixteen sequences, namely si791-DV27P, si079-DV25SP, si079-DV27SP, si079-DV29SP, si047-DV26SP, si079-DV34SP, si751-DV27P, si047-DV29SP, si791-DV29P, si047-DV25SP, si014-DV25P, si014-DV34P, and si014-DV32P, were used in an IC50 experiment to determine the IC50 concentration of each sequence. The experimental results are shown in Table 15.

[0426] Table 15: IC50 Experimental Results of Each Modified Sequence

[0427] In the table above, N / A represents a low upper limit of inhibition rate, which cannot fit the IC50.

[0428] As can be seen from Table 15, the IC50 values ​​of these 16 sequences are between 0.0004 nM and 0.0240 nM. This indicates that INHBE gene expression can be effectively inhibited at low concentrations.

[0429] Example 4: Inhibition of target genes and potential off-target genes by siRNA conjugates with anti-off-target modifications

[0430] In the prior art, there is a modification method that replaces the 6th or 7th nucleotide of the antisense strand of siRNA with ethylene glycol nucleic acid (GNA), which can disrupt the seed region of the antisense strand, thereby significantly reducing off-target effects and reducing hepatotoxicity. In addition, studies have found that replacing all the base pairs of the sense and antisense strands at the 1st to 8th nucleotide positions starting from the 5' end of the siRNA antisense strand with the corresponding DNA can significantly reduce the off-target effect of siRNA without affecting the activity of siRNA.

[0431] Therefore, in this embodiment, in order to reduce off-target effects, further off-target modifications are performed based on the modifications disclosed herein. Specifically, the 7th or 7th and 11th nucleotides of the antisense strand are replaced with DNA, and the nucleotides at the complementary pairing position of the 7th nucleotide of the antisense strand in the sense strand are also replaced with DNA to reduce off-target effects. The codes and specific technical meanings used are as follows: d7B11 off-target prevention: The 7th and 11th nucleotides of the antisense strand are replaced with DNA, and the nucleotides at the complementary pairing position of the 7th nucleotide of the antisense strand in the sense strand are also replaced with DNA.

[0432] d7B off-target prevention: The 7th nucleotide of the antisense strand is replaced with DNA, and the nucleotides at the complementary pairing position of the 7th nucleotide of the antisense strand in the sense strand are also replaced with DNA.

[0433] Table 16: Examples of siRNA conjugates with or without anti-off-target modification of this disclosure, 84 / 91 pages, 107 CN 121801914 A

[0434]

[0435] The synthesis methods of the modified sense strand and the modified antisense strand in this embodiment are the same as those in Example 2.Furthermore, the conjugation groups G101, G103, etc. mentioned above in this disclosure are connected to the 3' end of the siRNA positive strand. The connection method of the conjugation group can refer to the method given in the prior art.

[0436] The method of the siRNA conjugate inhibiting the INHBE gene in this embodiment is the same as that in Examples 2 and 3. The only difference is that the test sample is the siRNA conjugate of this disclosure.

[0437] The experimental results show that at concentrations of 40 pM to 25 nM, the modifiers with anti-off-target modification have a significant inhibitory effect on the target gene INHBE. Moreover, the inhibition rate of the modifiers for potential off-target genes is significantly lower than the inhibition rate for the target gene. This indicates that the anti-off-target modification does not affect the inhibitory effect of the modifiers modified by the template of this disclosure on the target gene, but can inhibit the off-target effect of some sequences.

[0438] (1) Different modified sequences have a significant inhibitory effect on the INHBE gene.

[0439] The inhibition rate of all test samples on the INHBE gene is shown in Table 17.

[0440] All template-modified sequences showed significant inhibitory effects on INHBE at a concentration of 25 nM. For example, the template-modified sequence si079-DV25SPG101 achieved an inhibition rate of 81.0%.

[0441] Table 17: Inhibition rate of INHBE gene by template modification and anti-off-target modification sequence 85 / 91 pages 108 CN 121801914 A

[0442] After template modification, anti-off-target design was performed, which showed significant inhibitory activity on INHBE gene expression. For example, when the sequence si079 was modified with template DV25SP and anti-off-target design was performed, the inhibition rate of the sequence si079-DV25SPd7B11G101 was as high as 76.9%.

[0443] (2) After modification with any one or more of the various modification methods disclosed in this invention, anti-off-target design was performed, which showed significant anti-off-target effect on some off-target genes and reduced the inhibitory effect on off-target genes.

[0444] As shown in Table 18, the experimental results show that: The template modification sequence disclosed herein, with its off-target prevention design, can reduce the inhibitory effect on off-target genes, i.e., it has an off-target prevention effect. Using the template modification sequence disclosed herein with its off-target prevention design, it has an off-target prevention effect, and the inhibition rate of off-target genes can be reduced by up to 26.7%.

[0445] Table 18: Inhibition rate of off-target genes by template modification sequences and their off-target prevention modifications

[0446] 1) Using only template modification design

[0447] Some sequences modified with templates have certain off-target effects. For example, the modified sequence si079-DV25SPG101 has an inhibition efficiency of 54.4% on the potential off-target gene MTFR1; the modified sequence si751-DV27PG101 has an inhibition efficiency of 80.1% on the potential off-target gene SYT12.

[0448] 2) Simultaneous use of anti-off-target design (represented by "d7B" or "d7B11" in the sequence number)

[0449] Some sequences that simultaneously use template modification and anti-off-target modification significantly reduce the inhibition rate of off-target genes and have obvious anti-off-target effects. For example, si079-DV25SPd7B11G101 reduced the inhibition rate of MTFR1 by 26.7%; si751-DV27Pd7BG101 reduced the inhibition rate of SYT12 by 15.2%.

[0450] Summary: 1. After template modification, anti-off-target design has obvious inhibitory activity on INHBE gene expression. For example, when sequence si079 is modified with template DV25SP and then anti-off-target design is performed, the inhibition rate of sequence si079-DV25SPd7B11G101 is as high as 76.9%.

[0451] 2. After using any one or more of the various modification methods disclosed in this invention, and then performing off-target design, there is a significant off-target effect on some off-target genes, reducing the inhibitory effect on off-target genes.

[0452] 1) Some sequences modified with template have a certain off-target effect, such as the modified sequence si079-DV25SPG101, which has an inhibition efficiency of 54.4% on the potential off-target gene MTFR1; the modified sequence si751-DV27PG101 has an inhibition efficiency of 80.1% on the potential off-target gene SYT12.

[0453] 2) Some sequences that simultaneously use template modification and off-target prevention modification have a significantly reduced inhibition rate on off-target genes, and have a significant off-target prevention effect. For example, si079-DV25SPd7B11G101 reduced the inhibition rate of MTFR1 by 26.7%; si751-DV27Pd7BG101 reduced the inhibition rate of SYT12 by 15.2%.

[0454] Example 5: Inhibitory effect of sequences modified with the template of this disclosure on INHBE mRNA in mouse liver

[0455] In this example, the modifiers in Example 4 were used, and the inhibitory effect of each modifier on INHBE in the liver at different time points was detected by qPCR using transgenic mice expressing the human INHBE gene.

[0456] 1. Experimental materials

[0457] Test drug: Modifiers in Example 4, see Table 16.

[0458] Solvent: Physiological saline

[0459] Experimental animals: 6-8 week old, SPF grade hINHBE transgenic male mice, weighing between 18g and 28g, were divided into groups of 10 mice each.

[0460] 2. Experimental Methods

[0461] Dosage Design and Grouping

[0462] Grouping and Administration: After acclimatization, mice were randomly divided into a negative control group (solvent control group) and a control group (received by the solvent control group) according to their body weight.The test group consisted of 10 animals per group. The drug was administered via a single subcutaneous injection (sc / once) at a dose of 1 mg / kg, a volume of 5 mL / kg, and a concentration of 0.2 mg / mL. The day of administration was recorded as day 0.

[0463] Animal grouping information is detailed in Table 19 below: Table 19: Grouping Information

[0464] Detection Indicators

[0465] (1) General Observation

[0466] Observations were made once a day from one week before administration until the end of the experiment.

[0467] Observation content: Animals were observed at the cage for death or near death, mental state, behavior, fecal characteristics, and the supply of feed and water.

[0468] Animals tested: All animals in the negative control group and the test drug group.

[0469] (2) Measurement of body weight and food intake

[0470] The curves of changes in mouse body weight and food intake were recorded. The body weight and food intake (non-fasting weight) of mice were recorded once a week on the day of administration (D0) and once a week after administration.

[0471] (3) Detection of INHBE mRNA expression in the liver

[0472] Detection time: day 14, day 28

[0473] INHBE mRNA level detection method: qPCR.

[0474] Detection animals: 5 animals in the negative control group and the test drug group were tested each time.

[0475] (4) Data processing and statistical analysis

[0476] The experimental data are expressed as mean ± standard deviation (Mean ± SD). The data analysis was performed using GraphPad Prism 10 analysis software. Two-way ANOVA and post-hoc tests were used for statistical analysis. Homogeneity of variance was tested using LSD test. Heterogeneity of variance was tested using Dunnett T3. p < 0.05 was considered statistically significant.

[0477] 3. Experimental results

[0478] The specific experimental results are shown in Table 20.

[0479] It can be seen that the expression of INHBE mRNA in the liver can be significantly inhibited. For example, the inhibition rate of si079-DV25SPd7B11G101 reached 89.9% on day 14.

[0480] (1) The sequences disclosed herein have a significant inhibitory effect on the expression of INHBE mRNA in the liver. For example, the inhibition rate of si079-DV25SPd7B11G101 reached 89.9% on day 14.

[0481] Table 20: Inhibition rate of different sequences on liver INHBE mRNA

[0482] It can be seen from Table 20 that the conjugates formed by each sequence and the GalNAc compound have a significant inhibitory effect on the expression of liver INHBE mRNA. For example, the inhibition rates of si079-DV25SPd7B11G101 on day 14 and day 21 were 89.9% and 22.2%, respectively.

[0483] This indicates that the sequence designed in this disclosure, modified with the template of this disclosure, or simultaneously using an off-target design, conjugated with a GalNAc compound, can be efficiently delivered to the liver of animals and significantly inhibit the expression of the INHBE gene.

[0484] Example 6: Inhibitory effect of the sequence modified with the template of this disclosure on mouse weight gain

[0485] In this example, some of the modifiers in Example 4 were used to establish a DIO (diet-induced obesity) model using transgenic mice expressing the human INHBE gene. The weight and body fat percentage at different time points were detected, and the inhibitory effect of each modifier on INHBE in the liver at different time points was detected by qPCR.

[0486] 1. Experimental Materials Specification 88 / 91 pages 111 CN 121801914 A

[0487] Test Drug: Modifiers in Example 4, including si079-DV25SPd7B11G101, si752-DV25SPd7B11G101, si791-DV26Pd7BG101, si047-DV26SPG101, si079-DV25SPG101, si791-DV29PG101, si079-DV29SPG101 and si079-DV25SPd7BG101, the sequences of the modifiers are shown in Table 16.

[0488] The positive serotype AC004285 is from Table 5C of US20250075214A1. Its positive serotype sequence is: 5'-(NAG37)s-(invAb)s-Cm-Um-Gm-Gm-Cm-Um-Um-Am-Uf-Am-Cf-Uf-Um-Um-Cm-Um-Um-Am-Am-Um-Ams-(invAb)-3' (SEQ ID NO. 908), and its antiserotype sequence is 5'-Ums-Afs-Um-Um-Af-Am-Gm-Am-Am-Am-Gm-Uf-Am-Uf-Am-Af-Gm-Cm-Cm-Amss-Gm-3' (SEQ ID NO. 908). 909), where the meanings of NAG37 and invAb are found in the patent document, and the meanings of the letters s, f, and m are the same as the corresponding meanings defined in other parts of this disclosure.

[0489] Solvent: physiological saline

[0490] Experimental animals: 6-8 week old, SPF grade hINHBE transgenic male mice, weighing between 18g and 28g, were grouped into control group (15 mice per group), 1 mpk dose group (8 mice per group), and 3 mpk dose group (9 mice per group).

[0491] 2. Experimental methods

[0492] Dosage design and grouping

[0493] Grouping and administration: After acclimatization, mice were randomly divided into negative control group and test drug group according to body weight and body fat percentage.The drug was administered via a single subcutaneous injection at a dose of 1 mg / kg or 3 mg / kg, with a volume of 5 mL / kg and a concentration of 0.2 mg / mL or 0.6 mg / mL. The day of administration was recorded as day 0.

[0494] Grouping information is detailed in Table 21 below: Table 21: Grouping Information

[0495] Detection Indicators

[0496] (1) General Observation

[0497] Observations were made once a day from one week before administration until the end of the experiment.

[0498] Observation content: Animals were observed at the cage for death or near death, mental state, behavior, fecal characteristics, and the supply of feed and water.

[0499] Animals tested: All animals in the negative control group and the test drug group.

[0500] (2) Measurement of body weight, body fat and food intake

[0501] Record the curves of changes in mouse body weight and food intake. Record mouse body weight (non-fasting weight) and food intake twice a week on the day of administration (D0) and after administration. Record mouse body fat percentage once a week.

[0502] (3) Detection of liver INHBE mRNA expression

[0503] Detection time: D28 (4 weeks after the first administration) and D55 (2 weeks after the second administration)

[0504] INHBE mRNA level detection method: qPCR.

[0505] Detection animals: 3-5 animals in the negative control group and the test drug group were tested each time.

[0506] (4) Data processing and statistical analysis

[0507] The experimental data are expressed as mean ± standard deviation (Mean ± SD). GraphPad Prism 10 analysis software was used for data analysis. Statistical analysis was performed using two-way ANOVA and post-hoc tests. Homogeneity of variance was determined by the LSD test, and unequal variance was determined by Dunnett's T3 test. p < 0.05 was considered statistically significant. (Instructions for use, pages 89 / 91, 112, CN 121801914 A)

[0508] 3. Experimental Results

[0509] The results of liver INHBE mRNA expression measurement are shown in Table 22.

[0510] It can be seen that these sequences can significantly inhibit INHBE mRNA expression in the liver. For example, si079-DV25SPd7B11G101, administered at 1 mg / kg, showed inhibition rates of 46.6% and 84.9% on days 28 and 55, respectively.

[0511] (1) The sequences disclosed herein have a significant inhibitory effect on INHBE mRNA expression in the liver. For example, si079-DV25SPd7B11G101, administered at 1 mg / kg, showed inhibition rates of 46.6% and 84.9% on days 28 and 55, respectively.

[0512] Table 22: Inhibition rate of different sequences on liver INHBE mRNA

[0513] (2) The sequences disclosed herein have a significant inhibitory effect on weight and body fat growth in DIO mice (as shown in Table 23). For example,When si791-DV26Pd7BG101 was administered at 1 mg / kg or 3 mpk, the percentage reduction in body weight and body fat on day 21 was 12.7% and 22.7%, respectively, compared with the saline control group.

[0514] Table 23: Percentage reduction in body weight and body fat by different sequences

[0515] As can be seen from Table 23, the conjugates formed by each sequence and GalNAc compound have a significant inhibitory effect on the growth of body weight and body fat. For example, when si791-DV26Pd7BG101 was administered at 1 mg / kg or 3 mpk, the percentage reduction in body weight and body fat on day 21 was 12.7% and 22.7%, respectively, compared with the saline control group.

[0516] This indicates that the sequences designed in this disclosure, modified with the template of this disclosure, or simultaneously using an anti-off-target design, conjugated with GalNAc compounds, can be efficiently delivered to the liver of animals and significantly inhibit the growth of body weight and body fat.

[0517] This disclosure designs a series of siRNAs based on the INHBE mRNA sequence, modifies them using a set of specific modification templates, and designs some sequences to prevent off-target effects. Results show that using multiple modification sequences, the inhibition rate can reach over 70%. Furthermore, when the modified sequences are conjugated with GalNAc compounds, they can be efficiently delivered to the animal liver, significantly inhibiting INHBE gene expression, body weight, and body fat growth. Abstract: The present invention discloses an siRNA duplex for targeted regulation of INHBE gene expression and a use thereof in the prevention and treatment of metabolism-related diseases. The present disclosure also relates to a corresponding conjugate and pharmaceutical composition. Results from cell-based and animal experiments show that the oligonucleotide duplex of the present disclosure can significantly inhibit INHBE gene expression and canbe used for the manufacture of a medicament for the prevention or treatment of atherosclerosis and other related diseases.

Claims

1. A siRNA double strand, characterized in that, The siRNA double strand comprises a sense strand and an antisense strand forming an inverse complementary double-stranded region. The antisense strand comprises at least 15, 16, 17, 18, or 19 consecutive nucleotides complementary to the target sequence as shown in SEQ ID NO: 907, or the antisense strand comprises at least 15, 16, 17, 18, or 19 consecutive nucleotide fragments from any of the sequences shown in SEQ ID NO: 13-24, 134-236, 238-240, or 252-260.

2. The siRNA double strand as described in claim 1, characterized in that, The positive chain comprises at least 17, 18, or 19 consecutive nucleotide fragments in any of the sequences shown in SEQ ID NO: 1~12, 25~127, 129~131, 243~251.

3. The siRNA double strand as described in claim 1, characterized in that, The siRNA duplex satisfies one or more of the following conditions: (1) The length of the reverse complementary double-stranded region is 17~21 bp; (2) The lengths of the sense strand and the antisense strand each independently comprise 19-23 nucleotides; (3) At least one strand contains a 3' overhang of at least one or at least two nucleotides; and, (4) The siRNA double strand is an siRNA used to suppress the expression of the INHBE gene.

4. The siRNA double strand as described in claim 1, characterized in that, The siRNA duplex comprises any one or a combination of at least two of the following oligonucleotide duplexes composed of sense and antisense strand pairings: The nucleotide sequence of the sense strand is shown in SEQ ID NO: 1; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 13; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 2; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 14; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 3; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 15; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 4; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 16; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 5; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 17; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 6; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 18; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 7; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 19; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 8; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 20; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 9; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 21; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 10; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 22; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 11; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 23; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 12; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 24; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 25; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 134; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 26; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 135; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 27; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 136; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 28; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 137; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 29; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 138; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 30; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 139; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 31; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 140; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 32; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 141; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 33; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 142; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 34; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 143; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 35; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 144; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 36; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 145; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 37; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 146; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 38; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 147; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 39; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 148; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 40; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 149; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 41; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 150; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 42; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 151; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 43; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 152; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 44; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 153; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 45; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 154; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 46; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 155; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 47; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 156; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 48; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 157; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 49; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 158; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 50; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 159; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 51; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 160; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 52; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 161; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 53; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 162; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 54; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 163; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 55; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 164; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 56; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 165; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 57; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 166; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 58; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 167; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 59; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 168; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 60; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 169; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 61; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 170; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 62; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 171; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 63; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 172; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 64; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 173; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 65; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 174; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 66; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 175; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 67; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 176; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 68; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 177; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 69; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 178; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 70; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 179; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 71; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 180; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 72; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 181; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 73; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 182; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 74; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 183; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 75; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 184; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 76; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 185; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 77; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 186; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 78; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 187; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 79; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 188; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 80; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 189; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 81; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 190; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 82; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 191; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 83; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 192; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 84; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 193; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 85; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 194; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 86; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 195; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 87; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 196; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 88; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 197; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 89; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 198; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 90; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 199; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 91; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 200; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 92; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 201; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 93; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 202; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 94; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 203; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 95; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 204; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 96; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 205; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 97; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 206; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 98; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 207; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 99; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 208; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 100; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 209; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 101; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 210; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 102; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 211; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 103; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 212; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 104; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 213; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 105; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 214; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 106; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 215; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 107; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 216; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 108; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 217; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 109; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 218; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 110; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 219; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 111; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 220; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 112; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 221; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 113; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 222; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 114; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 223; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 115; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 224; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 116; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 225; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 117; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 226; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 118; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 227; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 119; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 228; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 120; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 229; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 121; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 230; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 122; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 231; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 123; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 232; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 124; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 233; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 125; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 234; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 126; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 235; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 127; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 236; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 129; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 238; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 130; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 239; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 131; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 240; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 243; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 252; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 244; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 253; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 245; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 254; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 246; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 255; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 247; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 256; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 248; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 257; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 249; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 258; The nucleotide sequence of the sense strand is shown in SEQ ID NO: 250; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO: 259; and The nucleotide sequence of the sense strand is shown in SEQ ID NO: 251; and the nucleotide sequence of the antisense strand is shown in SEQ ID NO:

260.

5. The siRNA double strand as described in claim 1, characterized in that, The sense or antisense strand comprises at least one modified nucleotide, wherein the at least one modified nucleotide is selected from any or a combination of at least two of the following: deoxy-nucleotides, 3'-terminal deoxy-thymidine (dT) nucleotides, 2'-O-methyl modified nucleotides, 2'-fluorine modified nucleotides, 2'-deoxy-modified nucleotides, locked nucleotides, non-locked nucleotides, configuration-restricted nucleotides, restricted ethyl nucleotides, base-free nucleotides, 2'-amino-modified nucleotides, 2'-O-allyl- Modified nucleotides, 2'-C-alkyl-modified nucleotides, 2'-hydroxy-modified nucleotides, 2'-methoxyethyl-modified nucleotides, 2'-O-alkyl-modified nucleotides, morpholinonucleotides, aminophosphates, nucleotides containing non-natural bases, tetrahydropyran-modified nucleotides, 1,5-dehydrohexyl-modified nucleotides, cyclohexenyl-modified nucleotides, nucleotides containing thiophosphate groups, nucleotides containing methylphosphate groups, nucleotides containing 5'-phosphates, and nucleotides containing 5'-phosphate mimics.

6. The siRNA double strand as described in claim 5, characterized in that, The nucleotide modifications on the sense and antisense strands are 2' position modifications of the nucleotide ribose.

7. The siRNA double strand as described in claim 6, characterized in that, The 2'-position modification of the nucleotide ribose is selected from any one or a combination of several of 2'-methoxy, 2'-methoxyethyl, 2'-fluoro, 2'-benzyloxy, 2'-methylcarbonylamino, and 2'-pyridinemethoxy.

8. The siRNA double strand as described in claim 7, characterized in that, The 2' position of the nucleotide ribose is modified with an alternating combination of 2'-methoxy and 2'-fluoro compounds.

9. The siRNA double strand as described in claim 8, characterized in that, The 2' position of the nucleotide ribose is modified as follows: the odd-numbered positions of the sense strand are all 2'-fluorinated, and the even-numbered positions are all 2'-methoxyinated; and the odd-numbered positions of the antisense strand are all 2'-methoxyinated, and the even-numbered positions are all 2'-fluorinated.

10. The siRNA double strand as described in claim 1, characterized in that, Nucleotide monomers are linked to each other by 3',5'-phosphodiester bonds or 3',5'-thiophosphodiester bonds.

11. The siRNA double strand as described in claim 1, characterized in that, The 3',5'-phosphodiester bonds between nucleotides at the sequence ends of the siRNA double strand contain thiomodification and form chiral pure 3',5'-thiophosphodiester bonds; Preferably, the first to fourth nucleotides at the 5' end of the sense strand and / or the antisense strand contain one, two, or three 3',5'-phosphothioester bonds, and the first to fourth nucleotides at the 3' end of the antisense strand contain one, two, or three 3',5'-phosphothioester bonds.

12. The siRNA double strand as described in claim 1, characterized in that, Phosphorylation of the 5' carbon atom of the modified antisense 5'-terminal nucleotide glycoside, wherein the phosphorylation of the 5' carbon atom is selected from the following 5'-phosphorylating groups: 5'-vinylphosphonate group (5'-E-VP); 5'-methylphosphonate group (5'-MP); 5'-C-methylphosphate group; 5'-thiophosphate group (5'-PS); and 5'-phosphate group (5'-P), the structures of which are shown below: ; Where R represents hydrogen, hydroxyl, amino, or C. 1-4 Alkyl, aromatic, C 1-4 Alkoxy, C 1-4 Alkyl carbonyl amino or halogen; The bases are selected from adenine, guanine, cytosine, thymine, and uracil.

13. The siRNA double strand as described in claim 1, characterized in that, The siRNA duplex has the following modifications: The antisense chain has any of the following modifications: And / or, the chain of justice is modified in one of the following ways: Wherein, 2'-OMe represents 2'-methoxy; 2'-F represents 2'-fluoro; PS indicates that the nucleotide at the 5' end is connected to its adjacent nucleotide to the right by a 3',5'-thiophosphate bond; EVP represents 5'-vinyl-(E)-phosphonate; or, The antisense chain has any of the following modifications: And / or, the chain of justice is modified in one of the following ways: Wherein, 2'-OMe represents 2'-methoxy; 2'-F represents 2'-fluoro; PS indicates that the nucleotide at the 5' end is connected to the adjacent nucleotide on its right by a 3',5'-thiophosphate bond; and EVP represents 5'-vinyl-(E)-phosphonate.

14. The siRNA double strand as described in claim 13, characterized in that: The antisense chain is modified by modification method B, and the justice chain is modified by modification method a. The antisense chain is modified by modification method C, and the justice chain is modified by modification method a. The antisense chain is modified by modification method C, and the justice chain is modified by modification method b. The antisense chain is modified by modification method D, and the justice chain is modified by modification method b. The antisense chain is modified by modification method E, and the justice chain is modified by modification method b. The antisense chain is modified by modification method F, and the justice chain is modified by modification method b. The antisense chain is modified by modification method G, and the justice chain is modified by modification method b; or The antisense chain is modified by modification method H, and the justice chain is modified by modification method b. or, The antisense chain is modified by modification method B', and the justice chain is modified by modification method a'. The antisense chain is modified by the modification method C', and the justice chain is modified by the modification method a'. The antisense chain is modified by modification method C', and the justice chain is modified by modification method b'. The antisense chain is modified by the modification method D', and the justice chain is modified by the modification method b'. The antisense chain is modified by modification method E', and the justice chain is modified by modification method b'. The antisense chain is modified by the modification method F', and the justice chain is modified by the modification method b'. The antisense chain is modified by the modification method G', and the justice chain is modified by the modification method b'; or The antisense chain is modified by the modification method H', and the justice chain is modified by the modification method b'.

15. The siRNA double strand according to any one of claims 1-14, characterized in that, The siRNA duplex comprises any one or a combination of at least two of the oligonucleotide duplexes formed by pairing sense and antisense strands as shown in Tables 5 and 12.

16. The siRNA double strand as described in claim 1, characterized in that, The antisense strand and / or the sense strand are modified with a modifying group at any position from the second to the eleventh position starting from the 5' end of the nucleotide, wherein the modifying group is selected from UNA, GNA, and DNA, wherein the structures of UNA and GNA are as follows: ; The bases are selected from adenine, guanine, cytosine, thymine, and uracil; Preferably, the 7th position, or the 7th and 11th positions of the antisense strand, is replaced with DNA, and the nucleotides in the sense strand that are complementary to the 7th position of the antisense strand are also replaced with DNA.

17. A siRNA conjugate, characterized in that, The conjugate comprises a double-stranded siRNA as described in any one of claims 1-16, and a conjugate group attached thereto.

18. The conjugate as claimed in claim 17, characterized in that, The conjugation group is attached to the 3'-end or 5'-end of the positive strand of the oligonucleotide; and / or, the conjugation group is a GalNAc derivative attached using a divalent or trivalent branched linker arm.

19. The conjugate as claimed in claim 17, characterized in that, The conjugating group is: , Wherein, X is a hydroxyl protecting group or H, the hydroxyl protecting group being selected from acetyl, benzoyl or isobutyryl; Y is an amine protecting group or H, the amine protecting group being selected from formyl, acetyl, propionyl, n-butyryl or isobutyryl; n is an integer from 0 to 20; q, r and s are independently integers from 1 to 7.

20. The conjugate as claimed in claim 19, characterized in that, The conjugating group is: 。 21. The conjugate as claimed in claim 17, characterized in that, The conjugating group is: Where X is oxygen, -N(Y)-, or sulfur; Y is C 1-4 Alkyl or C 6-10 Aryl; R1 is oxygen or sulfur; R2 represents hydrogen, -NH2, or C. 1-4 Alkyl, C 6-10 Aryl, C 1-4 Alkoxy or halogen; A is -(CH2) a -、-(CH2CH2O) b -、-((CH2) c NHCO) d -or-((CH2) c CONH) d - where a is an integer from 1 to 15, b is an integer from 1 to 7, c is an integer from 1 to 7, and d is an integer from 1 to 5; B is -(CH2) e -, where e is an integer between 0 and 7; L is either -CONH- or -NHCO-; X1 is -(CH2) f -or-(CH2CH2O) f CH2-, f is an integer from 1 to 5; X2 is -(CH2) g - g is an integer from 1 to 6; Y1 is either 0 or 1; Y2 is 0, 1, or 2; When Y3 is 1, X3 is CH2; when Y3 is 2, X3 is CH; when Y3 is 3, X3 is carbon. m is an integer between 0 and 4; n is an integer between 0 and 4.

22. The conjugate as claimed in claim 21, characterized in that, The conjugating group is G4, G5, G6, or G7, and its structure is shown below: , , , 。 23. The conjugate as claimed in claim 17, characterized in that, The conjugate has any of the following structures: , , , ,and 。 24. The conjugate as claimed in claim 17, characterized in that, The conjugating group is: , Where X is oxygen, -N(Y)-, or sulfur; Y is C 1-4 Alkyl or C 6-10 Aryl; R1 is oxygen or sulfur; R2 represents hydrogen, -NH2, or C. 1-4 Alkyl, C 6-10 Aryl, C 1-4 Alkoxy or halogen; A is -(CH2) a -、-(CH2CH2O) b -、-((CH2) c NHCO) d -or-((CH2) c CONH) d - where a is an integer from 1 to 15, b is an integer from 1 to 7, c is an integer from 1 to 7, and d is an integer from 1 to 5; B is -(CH2) e -, where e is an integer between 0 and 7; L is either -CONH- or -NHCO-; X1 is -(CH2) f -or-(CH2CH2O) f CH2-, f is an integer from 1 to 5; X2 is -(CH2) g - g is an integer from 1 to 6; X3 is oxygen or sulfur; Y1 is either 0 or 1; Y2 is 0, 1, or 2; When Y3 is 1, X4 is CH2; when Y3 is 2, X4 is CH; when Y3 is 3, X3 is carbon. m is an integer between 0 and 4; n is an integer between 0 and 4; q is an integer between 0 and 4.

25. The conjugate as claimed in claim 24, characterized in that, The conjugating group is G101, G102, G103, G105, or G106: , , , ,or 。 26. The conjugate as claimed in claim 25, characterized in that, The conjugate has any of the following structures: , , , ,or 。 27. The conjugate as claimed in claim 17, characterized in that, The siRNA duplex comprises any one or a combination of at least two of the oligonucleotide duplexes formed by pairing sense and antisense strands as shown in Tables 5, 12 and 16. Wherein, any one or both of the sense chain and the antisense chain are connected to the conjugation group G4, G5, G6, G7, G101, G102, G103, G105 or G106.

28. The conjugate as claimed in claim 27, characterized in that, The conjugation group is attached to the 3' end of the positive chain.

29. A nucleic acid-protein complex, characterized in that, The nucleic acid protein complex comprises the double-stranded region of the siRNA double-stranded structure as described in any one of claims 1-16, and a nuclease; or, the nucleic acid protein complex comprises the antisense strand of the double-stranded region of the siRNA double-stranded structure as described in any one of claims 1-16, and a nuclease.

30. The nucleic acid-protein complex according to claim 29, characterized in that, The nuclease is an AGO protein.

31. A pharmaceutical composition, characterized in that, The pharmaceutical composition comprises a double-stranded siRNA as described in any one of claims 1-16, a conjugate as described in any one of claims 17-28, or a nucleic acid-protein complex as described in claims 29 or 30, and a pharmaceutically acceptable carrier.

32. Use of the siRNA duplex as described in any one of claims 1-16, the conjugate as described in any one of claims 17-28, the nucleic acid-protein complex as described in claim 29 or 30, or the pharmaceutical composition as described in claim 31 in the preparation of a medicament for the prevention and / or treatment of diseases related to INHBE gene expression.

33. The use of the siRNA double strand as described in any one of claims 1-16, the conjugate as described in any one of claims 17-28, the nucleic acid-protein complex as described in claim 29 or 30, or the pharmaceutical composition as described in claim 31 in the preparation of a medicament for the prevention and / or treatment of diabetes, obesity, including, for example, hyperlipidemia or dyslipidemia, insulin resistance or higher or altered insulin levels during fasting or metabolic challenges, hepatic steatosis or fatty liver disease, non-alcoholic steatohepatitis, elevated blood pressure and / or hypertension, metabolic syndrome, coronary artery disease and other atherosclerotic symptoms, and complications related to these diseases.